COMBINED VACCINE

Combining RNA and protein-based antigens in vaccines enhances immune response and efficacy against respiratory viruses, addressing production inefficiencies and immune response duration in current methods.

BR112025024360A2Pending Publication Date: 2026-11-10SEQIRUS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR112025024360
Authority / Receiving Office
BR · BR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-10
Filing Date
2024-05-10
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Current vaccine production methods, particularly egg-based and nucleic acid-based, are inefficient in producing sufficient quantities rapidly and effectively for respiratory viral infections like influenza, RSV, and SARS-CoV-2, with challenges in strain selection and immune response duration.

Method used

Combining RNA-based and protein-based antigens in a co-formulated vaccine, such as a self-amplifying mRNA vaccine with a protein-based adjuvant, to enhance immune response and antigen-specific IgG subclasses, providing immunogenic compositions that include polynucleotides and polypeptides encoding respiratory viruses and coronaviruses.

Benefits of technology

The co-formulated vaccines increase neutralization titers and induce balanced IgG1:IgG2a responses, offering improved immune responses and potential treatment or prevention of diseases like RSV, influenza, and SARS-CoV-2 infections.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure relates to compositions comprising multiple antigens of interest for use in vaccine formulations. The compositions comprise (a) a polynucleotide (such as an RNA) comprising a nucleotide sequence encoding an antigen and (b) an antigen polypeptide. The compositions can be used in inducing an immune response in a subject and / or in the treatment or prevention of a disease, such as a respiratory viral infection.
Need to check novelty before this filing date? Find Prior Art

Description

[001] This application claims priority from U.S. Patent Application No. 63 / 501,222, filed May 10, 2023, entitled Combination vaccine, the full content of which is incorporated herein by reference. SEQUENCE LISTING

[002] This application is submitted together with a Sequence Listing in electronic format. All content of the Sequence Listing is incorporated by reference. FIELD

[003] The present invention relates to compositions comprising multiple antigens of interest for use in vaccine formulations. BACKGROUND

[004] Respiratory viral infections pose a significant threat to human health. Infections, such as those caused by influenza virus and severe acute respiratory syndrome coronavirus (SARS-CoV), are known to cause global pandemics, killing millions of people worldwide. Recently, SARS-CoV-2 was responsible for the current global pandemic of the highly infectious coronavirus disease 2019 (COVID-19). Furthermore, respiratory syncytial virus (RSV) is the single most common cause of hospitalization for respiratory problems in infants, and reinfection remains common in adulthood. While some vaccines are already available for viral infections such as influenza, SARS-CoV-2, and RSV, such as mRNA vaccines developed to treat or prevent SARS-CoV-2 infection, further improvements can be made to increase their effectiveness and / or enhance treatment strategies. Petition 870260001818, dated 08 / 01 / 2026, page 6 / 357 2 / 291

[005] Currently, egg-based manufacturing processes are the most common form of vaccine production. This process requires considerable time to optimize virus growth in eggs, as well as resources (i.e., eggs) to produce sufficient quantities of vaccine, particularly during a pandemic. Furthermore, due to the long development time required, vaccine strain selection is performed before the vaccine is available, making it difficult to respond to changes in the virus. Vaccines have also been produced using cell-based manufacturing processes, involving cultured mammalian cells (e.g., Madin-Darby canine kidney cells, or MDCK cells) instead of eggs, and virus-based platforms, involving recombinant viruses (e.g., baculovirus encoding an influenza antigen), have also been used.

[006] The need remains to develop specific and effective viral vaccines that can be produced more rapidly and on a wider scale than current egg-based techniques for the treatment or prevention of respiratory viral infections such as influenza, RSV, and SARS-CoV-2. Nucleic acid-based vaccines offer distinct advantages over the current egg-based production platform, although some challenges still persist. For example, the inherently unstable nature of mRNA means that most RNA-based vaccines have limited ability to deliver antigen at the dose and duration needed to produce a strong and lasting immune response.

[007] Therefore, it will become evident to the specialist that there is a need, in the area, for compositions with greater utility and / or improved efficacy, suitable for use as vaccines. SUMMARY

[008] The present description is based on the discoveries of the inventors Petition 870260001818, dated 08 / 01 / 2026, page 7 / 357 3 / 291 factors suggest that combining an RNA-based antigen with a protein-based antigen in an immunogenic compound, such as a vaccine, can enhance an individual's immune response to the immunogenic compound.

[009] It was further found that administration of a co-formulated RNA vaccine, for example, a self-amplifying mRNA vaccine (sa-mRNA) and a protein-based adjuvant vaccine, results in increased neutralization titers against the antigens of both vaccines and influences the antigen-specific IgG subclasses induced by recombinant protein vaccines. For example, the antigen-specific IgG1:IgG2a ratio induced by the protein adjuvant vaccine was found to be significantly altered towards a balanced IgG1:IgG2a response when co-formulated with an RNA vaccine, for example, a self-amplifying mRNA vaccine (sa-mRNA). These improvements were observed in comparison with, for example, RNA vaccines and protein vaccines that are co-administered at sites distant from each other.

[0010] It was also found that an RNA vaccine and a protein vaccine co-administered locally provided similar benefits to those of an RNA vaccine and a protein vaccine co-formulated, compared to RNA vaccines and protein vaccines co-administered at sites distant from each other.

[0011] The findings therefore provide the basis for immunogenic compositions comprising (i) an RNA comprising a nucleotide sequence encoding one or more antigens of interest selected from the group consisting of a respiratory syncytial virus (RSV), an influenza virus and / or a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and (ii) a polypeptide antigen selected from the group consisting of an RSV, an influenza virus and / or a SARS-CoV-2. Furthermore, the inventors' findings for Petition 870260001818, dated 08 / 01 / 2026, page 8 / 357 4 / 291 provide the basis for methods of treating, preventing, or delaying the progression of a disease or disorder (e.g., RSV, influenza, SARS-CoV-2 infection, COVID-19, or ARDS) in an individual, through the administration of the immunogenic compositions of the present invention.

[0012] Thus, the present disclosure offers an immunogenic composition comprising:

[0013] (i) a polynucleotide comprising a nucleotide sequence encoding an antigen selected from the group consisting of a respiratory syncytial virus (RSV), influenza and a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0014] (ii) an antigenic polypeptide selected from the group consisting of an RSV, influenza and SARS-CoV-2.

[0015] When discussing a selected antigen from the group consisting of a respiratory syncytial virus (RSV), influenza, and a severe acute respiratory syndrome coronavirus (SARS-CoV-2), the qualified professional will recognize that the antigen is from the aforementioned virus.

[0016] For example, the immunogenic composition comprises:

[0017] a) a polynucleotide comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0018] b) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[0019] In another example, the immunogenic composition comprises:

[0020] a) a polynucleotide comprising a sequence of nucleotides encoding an antigen of a coronavirus of the syndrome Petition 870260001818, dated 08 / 01 / 2026, page 9 / 357 5 / 291 severe acute respiratory infection (SARS-CoV-2), in which the nucleotide sequence is operationally linked to a regulatory element; and

[0021] b) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[0022] In another example, the immunogenic composition comprises:

[0023] a) a polynucleotide comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0024] b) an antigenic polypeptide of influenza.

[0025] In another example, the immunogenic composition comprises:

[0026] a) a polynucleotide comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0027] b) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[0028] In another example, the immunogenic composition comprises:

[0029] a) a polynucleotide comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0030] b) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[0031] In another example, the immunogenic composition comprises Petition 870260001818, dated 08 / 01 / 2026, page 10 / 357 6 / 291 of:

[0032] a) a polynucleotide comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0033] b) an antigenic polypeptide of influenza.

[0034] In another example, the immunogenic composition comprises:

[0035] a) a polynucleotide comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0036] b) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[0037] In another example, the immunogenic composition comprises:

[0038] a) a polynucleotide comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0039] b) an antigenic polypeptide of influenza.

[0040] In another example, the immunogenic composition comprises:

[0041] a) a polynucleotide comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0042] b) an antigenic polypeptide of SARS-CoV-2.

[0043] For example, the immunogenic composition comprises: Petition 870260001818, dated 08 / 01 / 2026, page 11 / 357 7 / 291

[0044] (i) an RNA comprising a nucleotide sequence encoding an antigen selected from the group consisting of a respiratory syncytial virus (RSV), an influenza virus and / or a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0045] (ii) an antigenic polypeptide selected from the group consisting of an RSV, an influenza virus and / or a SARS-CoV-2.

[0046] For example, the immunogenic composition comprises:

[0047] a) an RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0048] b) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[0049] In another example, the immunogenic composition comprises:

[0050] a) an RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0051] b) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[0052] In another example, the immunogenic composition comprises:

[0053] a) an RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0054] b) an influenza antigenic polypeptide. Petition 870260001818, dated 08 / 01 / 2026, page 12 / 357 8 / 291

[0055] In another example, the immunogenic composition comprises:

[0056] a) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is functionally linked to a regulatory element; and

[0057] b) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[0058] In another example, the immunogenic composition comprises:

[0059] a) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is functionally linked to a regulatory element; and

[0060] b) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[0061] In another example, the immunogenic composition comprises:

[0062] a) an RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0063] b) an antigenic polypeptide of influenza.

[0064] In another example, the immunogenic composition comprises:

[0065] a) an RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0066] b) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[0067] In another example, the immunogenic composition comprises Petition 870260001818, dated 08 / 01 / 2026, page 13 / 357 9 / 291 of:

[0068] a) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is functionally linked to a regulatory element; and

[0069] b) an influenza antigenic polypeptide.

[0070] In another example, the immunogenic composition comprises:

[0071] a) an RNA comprising a nucleotide sequence encoding an antigen of a SARS-CoV-2, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0072] b) an antigenic polypeptide of SARS-CoV-2.

[0073] In another example, the immunogenic composition comprises:

[0074] (i) a cRNA comprising a nucleotide sequence encoding an antigen selected from the group consisting of a respiratory syncytial virus (RSV), an influenza virus and / or a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0075] (ii) an antigenic polypeptide selected from the group consisting of an RSV, an influenza virus and / or a SARS-CoV-2.

[0076] For example, the immunogenic composition comprises:

[0077] a) a cRNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0078] b) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[0079] In another example, the immunogenic composition comprises Petition 870260001818, dated 08 / 01 / 2026, page 14 / 357 10 / 291 of:

[0080] a) a cRNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0081] b) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[0082] In another example, the immunogenic composition comprises:

[0083] a) a cRNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0084] b) an influenza antigenic polypeptide.

[0085] In another example, the immunogenic composition comprises:

[0086] a) a cRNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0087] b) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[0088] In another example, the immunogenic composition comprises:

[0089] a) a cRNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0090] b) an antigenic polypeptide of a respiratory syncytial virus (RSV). Petition 870260001818, dated 08 / 01 / 2026, page 15 / 357 11 / 291

[0091] In another example, the immunogenic composition comprises:

[0092] a) a cRNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0093] b) an antigenic polypeptide of influenza.

[0094] In another example, the immunogenic composition comprises:

[0095] a) a cRNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0096] b) an antigenic polypeptide of an RSV.

[0097] In another example, the immunogenic composition comprises:

[0098] a) a cRNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[0099] b) an antigenic polypeptide of influenza.

[00100] In another example, the immunogenic composition comprises:

[00101] a) a cRNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00102] b) an antigenic polypeptide of SARS-CoV-2.

[00103] In another example, the immunogenic composition comprises: Petition 870260001818, dated 08 / 01 / 2026, page 16 / 357 12 / 291

[00104] (i) a self-replicating RNA comprising a nucleotide sequence encoding an antigen selected from the group consisting of a respiratory syncytial virus (RSV), an influenza virus and / or a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00105] (ii) an antigenic polypeptide selected from the group consisting of an RSV, an influenza virus and / or a SARS-CoV-2.

[00106] For example, the immunogenic composition comprises:

[00107] a) a self-replicating RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00108] b) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00109] In another example, the immunogenic composition comprises:

[00110] a) a self-replicating RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00111] b) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00112] In another example, the immunogenic composition comprises:

[00113] a) a self-replicating RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element Petition 870260001818, dated 08 / 01 / 2026, page 17 / 357 13 / 291 lador; and

[00114] b) an antigenic polypeptide of influenza.

[00115] In another example, the immunogenic composition comprises:

[00116] a) a self-replicating RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00117] b) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00118] In another example, the immunogenic composition comprises:

[00119] a) a self-replicating RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00120] b) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00121] In another example, the immunogenic composition comprises:

[00122] a) a self-replicating RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00123] b) an antigenic polypeptide of influenza.

[00124] In another example, the immunogenic composition comprises:

[00125] a) a self-replicating RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), in which the nucleotide sequence is linked in a way Petition 870260001818, dated 08 / 01 / 2026, page 18 / 357 14 / 291 operational to a regulatory element; and

[00126] b) an antigenic polypeptide of an RSV.

[00127] In another example, the immunogenic composition comprises:

[00128] a) a self-replicating RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00129] b) an antigenic polypeptide of influenza.

[00130] In another example, the immunogenic composition comprises:

[00131] a) a self-replicating RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00132] b) an antigenic polypeptide of SARS-CoV-2.

[00133] In one example, an immunogenic disclosure composition comprises several polynucleotides, wherein each polynucleotide encodes different polypeptide sequences. In another example, an immunogenic disclosure composition comprises several RNAs, wherein each RNA encodes different polypeptide sequences. In yet another example, an immunogenic disclosure composition comprises several cRNAs, wherein each cRNA encodes different polypeptide sequences. In yet another example, an immunogenic composition of the present invention comprises multiple self-replicating RNAs, wherein each self-replicating RNA encodes different polypeptide sequences.

[00134] Thus, in one example, the immunogenic composition comprises: Petition 870260001818, dated 08 / 01 / 2026, page 19 / 357 15 / 291

[00135] (i) a polynucleotide comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element;

[00136] (ii) a polynucleotide comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00137] (iii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00138] In one example, the immunogenic composition comprises, in the order of 5' to 3':

[00139] (i) the polynucleotide comprising a sequence of nucleotides encoding a respiratory syncytial virus (RSV) antigen;

[00140] (ii) the polynucleotide comprising a sequence of nucleotides encoding an influenza antigen.

[00141] In one example, the immunogenic composition comprises, in the order of 5' to 3':

[00142] (i) the polynucleotide comprising a nucleotide sequence encoding an influenza antigen, and

[00143] (ii) the polynucleotide comprising a sequence of nucleotides encoding a respiratory syncytial virus (RSV) antigen.

[00144] In another example, the immunogenic composition comprises:

[00145] (i) a polynucleotide comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; Petition 870260001818, dated 08 / 01 / 2026, page 20 / 357 16 / 291

[00146] (ii) a polynucleotide comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00147] (iii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00148] In one example, the immunogenic composition comprises, in the order of 5' to 3':

[00149] (i) the polynucleotide comprising a sequence of nucleotides encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2);

[00150] (ii) the polynucleotide comprising a sequence of nucleotides encoding an influenza antigen.

[00151] In one example, the immunogenic composition comprises, in the order of 5' to 3':

[00152] (i) the polynucleotide comprising a sequence of nucleotides encoding an influenza antigen; and

[00153] (ii) the polynucleotide comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00154] In another example, the immunogenic composition comprises:

[00155] (i) a polynucleotide comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element;

[00156] (ii) a polynucleotide comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and Petition 870260001818, dated 08 / 01 / 2026, page 21 / 357 17 / 291

[00157] (iii) an influenza antigenic polypeptide.

[00158] In one example, the immunogenic composition comprises, in the order of 5' to 3':

[00159] (i) the polynucleotide comprising a sequence of nucleotides encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2);

[00160] (ii) the polynucleotide comprising a sequence of nucleotides encoding an antigen of a respiratory syncytial virus (RSV).

[00161] In one example, the immunogenic composition comprises, in the order of 5' to 3':

[00162] (i) the polynucleotide comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV); and

[00163] (ii) the polynucleotide comprising a sequence of nucleotides encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00164] In another example, the immunogenic composition comprises:

[00165] (i) a polynucleotide comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element;

[00166] (ii) a polynucleotide comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00167] (iii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2). Petition 870260001818, dated 08 / 01 / 2026, page 22 / 357 18 / 291

[00168] In another example, the immunogenic composition comprises:

[00169] (i) a polynucleotide comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element;

[00170] (ii) a polynucleotide comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00171] (iii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00172] In another example, the immunogenic composition comprises:

[00173] (i) a polynucleotide comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00174] (ii) a polynucleotide comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00175] (iii) an influenza antigenic polypeptide.

[00176] For example, the immunogenic composition comprises:

[00177] (i) a polynucleotide comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element;

[00178] (ii) a polynucleotide comprising a nucleotide sequence encoding an antigen of a syndrome coronavirus Petition 870260001818, dated 08 / 01 / 2026, page 23 / 357 19 / 291 severe acute respiratory infection (SARS-CoV-2), in which the nucleotide sequence is operationally linked to a regulatory element; and

[00179] (iii) an antigenic polypeptide of respiratory syncytial virus (RSV).

[00180] In another example, the immunogenic composition comprises:

[00181] (i) a polynucleotide comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element;

[00182] (ii) a polynucleotide comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00183] (iii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00184] In another example, the immunogenic composition comprises:

[00185] (i) a polynucleotide comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element;

[00186] (ii) a polynucleotide comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00187] (iii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2). Petition 870260001818, dated 08 / 01 / 2026, page 24 / 357 20 / 291

[00188] In another example, the immunogenic composition comprises:

[00189] (i) a polynucleotide comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element;

[00190] (ii) a polynucleotide comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00191] (iii) an antigenic polypeptide of respiratory syncytial virus (RSV).

[00192] For example, the immunogenic composition comprises:

[00193] (i) a polynucleotide comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00194] (ii) a polynucleotide comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00195] (iii) an antigenic polypeptide of respiratory syncytial virus (RSV).

[00196] In another example, the immunogenic composition comprises:

[00197] (i) a polynucleotide comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element;

[00198] (ii) a polynucleotide comprising a sequence of Petition 870260001818, dated 08 / 01 / 2026, page 25 / 357 21 / 291 nucleotides that encode an influenza antigen, where the nucleotide sequence is operationally linked to a regulatory element; and

[00199] (iii) an influenza antigenic polypeptide.

[00200] In another example, the immunogenic composition comprises:

[00201] (i) a polynucleotide comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element;

[00202] (ii) a polynucleotide comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00203] (iii) an influenza antigenic polypeptide.

[00204] In another example, the immunogenic composition comprises:

[00205] (i) a polynucleotide comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00206] (ii) a polynucleotide comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00207] (iii) an antigenic polypeptide of respiratory syncytial virus (RSV).

[00208] For example, the immunogenic composition comprises:

[00209] (i) a polynucleotide comprising a nucleotide sequence encoding an antigen of a syndrome coronavirus Petition 870260001818, dated 08 / 01 / 2026, page 26 / 357 22 / 291 severe acute respiratory infection (SARS-CoV-2), in which the nucleotide sequence is operationally linked to a regulatory element;

[00210] (ii) a polynucleotide comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00211] (iii) an influenza antigenic polypeptide.

[00212] In another example, the immunogenic composition comprises:

[00213] (i) a polynucleotide comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00214] (ii) a polynucleotide comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00215] (iii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00216] In another example, the immunogenic composition comprises:

[00217] (i) a polynucleotide comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00218] (ii) a polynucleotide comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element Petition 870260001818, dated 08 / 01 / 2026, page 27 / 357 23 / 291 lador; and

[00219] (iii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00220] In another example, the immunogenic composition comprises:

[00221] (i) a polynucleotide comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element;

[00222] (ii) a polynucleotide comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00223] (iii) an influenza antigenic polypeptide.

[00224] For example, the immunogenic composition comprises:

[00225] (i) an RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element;

[00226] (ii) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00227] (iii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00228] In one example, the immunogenic composition comprises, in the order of 5' to 3':

[00229] (i) RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen;

[00230] (ii) RNA comprising a sequence of nucleotides Petition 870260001818, dated 08 / 01 / 2026, page 28 / 357 24 / 291 which codes for an influenza antigen.

[00231] In one example, the immunogenic composition comprises, in the order of 5' to 3':

[00232] (i) RNA comprising a nucleotide sequence encoding an influenza antigen, and

[00233] (ii) RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen.

[00234] In another example, the immunogenic composition comprises:

[00235] (i) an RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element;

[00236] (ii) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00237] (iii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00238] In one example, the immunogenic composition comprises, in the order of 5' to 3':

[00239] (i) RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2);

[00240] (ii) RNA comprising a nucleotide sequence encoding an influenza antigen.

[00241] In one example, the immunogenic composition comprises, in the order of 5' to 3':

[00242] (i) RNA comprising a nucleotide sequence encoding an influenza antigen; and Petition 870260001818, dated 08 / 01 / 2026, page 29 / 357 25 / 291

[00243] (ii) RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00244] In another example, the immunogenic composition comprises:

[00245] (i) an RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element;

[00246] (ii) an RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00247] (iii) an influenza antigenic polypeptide.

[00248] In one example, the immunogenic composition comprises, in the order of 5' to 3':

[00249] (i) RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2);

[00250] (ii) RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV).

[00251] In one example, the immunogenic composition comprises, in the order of 5' to 3':

[00252] (i) RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV); and

[00253] (ii) RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00254] In another example, the immunogenic composition comprises: Petition 870260001818, dated 08 / 01 / 2026, page 30 / 357 26 / 291

[00255] (i) an RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element;

[00256] (ii) an RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00257] (iii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00258] In another example, the immunogenic composition comprises:

[00259] (i) an RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), wherein the nucleotide sequence is operatively linked to a regulatory element;

[00260] (ii) an RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00261] (iii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00262] In another example, the immunogenic composition comprises:

[00263] (i) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00264] (ii) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; Petition 870260001818, dated 08 / 01 / 2026, page 31 / 357 27 / 291 and

[00265] (iii) an influenza antigenic polypeptide.

[00266] For example, the immunogenic composition comprises:

[00267] (i) an RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element;

[00268] (ii) an RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00269] (iii) an antigenic polypeptide of respiratory syncytial virus (RSV).

[00270] In another example, the immunogenic composition comprises:

[00271] (i) an RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element;

[00272] (ii) an RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00273] (iii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00274] In another example, the immunogenic composition comprises:

[00275] (i) an RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a Petition 870260001818, dated 08 / 01 / 2026, page 32 / 357 28 / 291 regulating element;

[00276] (ii) an RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00277] (iii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00278] In another example, the immunogenic composition comprises:

[00279] (i) an RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element;

[00280] (ii) an RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00281] (iii) an antigenic polypeptide of respiratory syncytial virus (RSV).

[00282] For example, the immunogenic composition comprises:

[00283] (i) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00284] (ii) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00285] (iii) an antigenic polypeptide of respiratory syncytial virus (RSV).

[00286] In another example, the immunogenic composition comprises Petition 870260001818, dated 08 / 01 / 2026, page 33 / 357 29 / 291 of:

[00287] (i) an RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element;

[00288] (ii) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00289] (iii) an influenza antigenic polypeptide.

[00290] In another example, the immunogenic composition comprises:

[00291] (i) an RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element;

[00292] (ii) an RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00293] (iii) an influenza antigenic polypeptide.

[00294] In another example, the immunogenic composition comprises:

[00295] (i) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00296] (ii) an RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and Petition 870260001818, dated 08 / 01 / 2026, page 34 / 357 30 / 291

[00297] (iii) an antigenic polypeptide of respiratory syncytial virus (RSV).

[00298] For example, the immunogenic composition comprises:

[00299] (i) an RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element;

[00300] (ii) an RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00301] (iii) an influenza antigenic polypeptide.

[00302] In another example, the immunogenic composition comprises:

[00303] (i) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00304] (ii) an RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00305] (iii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00306] In another example, the immunogenic composition comprises:

[00307] (i) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00308] (ii) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nuPetition 870260001818, dated 08 / 01 / 2026, page 35 / 357 31 / 291 nucleotides are operationally linked to a regulatory element; and

[00309] (iii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00310] In another example, the immunogenic composition comprises:

[00311] (i) an RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element;

[00312] (ii) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00313] (iii) an influenza antigenic polypeptide.

[00314] For example, the immunogenic composition comprises:

[00315] (i) a cRNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element;

[00316] (ii) a cRNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00317] (iii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00318] In one example, the immunogenic composition comprises, in the order of 5' to 3':

[00319] (i) cRNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen; Petition 870260001818, dated 08 / 01 / 2026, page 36 / 357 32 / 291

[00320] (ii) cRNA comprising a nucleotide sequence encoding an influenza antigen.

[00321] In one example, the immunogenic composition comprises, in the order of 5' to 3':

[00322] (i) cRNA comprising a nucleotide sequence encoding an influenza antigen, and

[00323] (ii) cRNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen.

[00324] In another example, the immunogenic composition comprises:

[00325] (i) a cRNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element;

[00326] (ii) a cRNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00327] (iii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00328] In one example, the immunogenic composition comprises, in the order of 5' to 3':

[00329] (i) cRNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2);

[00330] (ii) cRNA comprising a nucleotide sequence encoding an influenza antigen.

[00331] In one example, the immunogenic composition comprises, in the order of 5' to 3':

[00332] (i) cRNA comprising a sequence of nucleotides Petition 870260001818, dated 08 / 01 / 2026, page 37 / 357 33 / 291 deos that encodes an influenza antigen; and

[00333] (ii) cRNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00334] In another example, the immunogenic composition comprises:

[00335] (i) a cRNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element;

[00336] (ii) a cRNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00337] (iii) an influenza antigenic polypeptide.

[00338] In one example, the immunogenic composition comprises, in the order of 5' to 3':

[00339] (i) cRNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2);

[00340] (ii) cRNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV).

[00341] In one example, the immunogenic composition comprises, in the order of 5' to 3':

[00342] (i) cRNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV); and

[00343] (ii) cRNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2). Petition 870260001818, dated 08 / 01 / 2026, page 38 / 357 34 / 291

[00344] In another example, the immunogenic composition comprises:

[00345] (i) a cRNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element;

[00346] (ii) a cRNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00347] (iii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00348] In another example, the immunogenic composition comprises:

[00349] (i) a cRNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element;

[00350] (ii) a cRNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00351] (iii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00352] In another example, the immunogenic composition comprises:

[00353] (i) a cRNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00354] (ii) a cRNA comprising a sequence of nucleotides Petition 870260001818, dated 08 / 01 / 2026, page 39 / 357 35 / 291 deos that encodes an influenza antigen, in which the nucleotide sequence is operationally linked to a regulatory element; and

[00355] (iii) an influenza antigenic polypeptide.

[00356] For example, the immunogenic composition comprises:

[00357] (i) a cRNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element;

[00358] (ii) a cRNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00359] (iii) an antigenic polypeptide of respiratory syncytial virus (RSV).

[00360] In another example, the immunogenic composition comprises:

[00361] (i) a cRNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element;

[00362] (ii) a cRNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00363] (iii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00364] In another example, the immunogenic composition comprises:

[00365] (i) a cRNA comprising a sequence of nucleotides Petition 870260001818, dated 08 / 01 / 2026, page 40 / 357 36 / 291 deos that encodes a respiratory syncytial virus (RSV) antigen, in which the nucleotide sequence is operatively linked to a regulatory element;

[00366] (ii) a cRNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00367] (iii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00368] In another example, the immunogenic composition comprises:

[00369] (i) a cRNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element;

[00370] (ii) a cRNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00371] (iii) an antigenic polypeptide of respiratory syncytial virus (RSV).

[00372] For example, the immunogenic composition comprises:

[00373] (i) a cRNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00374] (ii) a cRNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00375] (iii) an antigenic polypeptide of respiratory syncytial virus Petition 870260001818, dated 08 / 01 / 2026, page 41 / 357 37 / 291 (RSV).

[00376] In another example, the immunogenic composition comprises:

[00377] (i) a cRNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element;

[00378] (ii) a cRNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00379] (iii) an influenza antigenic polypeptide.

[00380] In another example, the immunogenic composition comprises:

[00381] (i) a cRNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element;

[00382] (ii) a cRNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00383] (iii) an influenza antigenic polypeptide.

[00384] In another example, the immunogenic composition comprises:

[00385] (i) a cRNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00386] (ii) a cRNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, in Petition 870260001818, dated 08 / 01 / 2026, page 42 / 357 38 / 291 that the nucleotide sequence is operationally linked to a regulatory element; and

[00387] (iii) an antigenic polypeptide of respiratory syncytial virus (RSV).

[00388] For example, the immunogenic composition comprises:

[00389] (i) a cRNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element;

[00390] (ii) a cRNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00391] (iii) an influenza antigenic polypeptide.

[00392] In another example, the immunogenic composition comprises:

[00393] (i) a cRNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00394] (ii) a cRNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00395] (iii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00396] In another example, the immunogenic composition comprises:

[00397] (i) a cRNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; Petition 870260001818, dated 08 / 01 / 2026, page 43 / 357 39 / 291

[00398] (ii) a cRNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00399] (iii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00400] In another example, the immunogenic composition comprises:

[00401] (i) a cRNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element;

[00402] (ii) a cRNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00403] (iii) an influenza antigenic polypeptide.

[00404] For example, the immunogenic composition comprises:

[00405] (i) a self-replicating RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element;

[00406] (ii) a self-replicating RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00407] (iii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00408] In one example, the immunogenic composition comprises, in the order of 5' to 3': Petition 870260001818, dated 08 / 01 / 2026, page 44 / 357 40 / 291

[00409] (i) self-replicating RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen;

[00410] (ii) self-replicating RNA comprising a nucleotide sequence encoding an influenza antigen.

[00411] In one example, the immunogenic composition comprises, in the order of 5' to 3':

[00412] (i) self-replicating RNA comprising a nucleotide sequence encoding an influenza antigen, and

[00413] (ii) self-replicating RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen.

[00414] In another example, the immunogenic composition comprises:

[00415] (i) a self-replicating RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operatively linked to a regulatory element;

[00416] (ii) a self-replicating RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00417] (iii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00418] In one example, the immunogenic composition comprises, in the order of 5' to 3':

[00419] (i) self-replicating RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); Petition 870260001818, dated 08 / 01 / 2026, page 45 / 357 41 / 291

[00420] (ii) self-replicating RNA comprising a nucleotide sequence encoding an influenza antigen.

[00421] In one example, the immunogenic composition comprises, in the order of 5' to 3':

[00422] (i) self-replicating RNA comprising a nucleotide sequence encoding an influenza antigen; and

[00423] (ii) self-replicating RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00424] In another example, the immunogenic composition comprises:

[00425] (i) a self-replicating RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operatively linked to a regulatory element;

[00426] (ii) a self-replicating RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00427] (iii) an influenza antigenic polypeptide.

[00428] In one example, the immunogenic composition comprises, in the order of 5' to 3':

[00429] (i) self-replicating RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2);

[00430] (ii) self-replicating RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV).

[00431] In one example, the immunogenic composition comprises, Petition 870260001818, dated 08 / 01 / 2026, page 46 / 357 42 / 291 in the order of 5' to 3':

[00432] (i) self-replicating RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV); and

[00433] (ii) self-replicating RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00434] In another example, the immunogenic composition comprises:

[00435] (i) a self-replicating RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operatively linked to a regulatory element;

[00436] (ii) a self-replicating RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00437] (iii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00438] In another example, the immunogenic composition comprises:

[00439] (i) a self-replicating RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element;

[00440] (ii) a self-replicating RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), wherein the nucleotide sequence is linked to Petition 870260001818, dated 08 / 01 / 2026, page 47 / 357 43 / 291 operational form to a regulatory element; and

[00441] (iii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00442] In another example, the immunogenic composition comprises:

[00443] (i) a self-replicating RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00444] (ii) a self-replicating RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00445] (iii) an influenza antigenic polypeptide.

[00446] For example, the immunogenic composition comprises:

[00447] (i) a self-replicating RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operatively linked to a regulatory element;

[00448] (ii) a self-replicating RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00449] (iii) an antigenic polypeptide of respiratory syncytial virus (RSV).

[00450] In another example, the immunogenic composition comprises:

[00451] (i) a self-replicating RNA comprising a sequence Petition 870260001818, dated 08 / 01 / 2026, page 48 / 357 44 / 291 nucleotides encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element;

[00452] (ii) a self-replicating RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00453] (iii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00454] In another example, the immunogenic composition comprises:

[00455] (i) a self-replicating RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element;

[00456] (ii) a self-replicating RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00457] (iii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00458] In another example, the immunogenic composition comprises:

[00459] (i) a self-replicating RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operatively linked to a regulatory element;

[00460] (ii) a self-replicating RNA comprising a sequence Petition 870260001818, dated 08 / 01 / 2026, page 49 / 357 45 / 291 nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, where the nucleotide sequence is operationally linked to a regulatory element; and

[00461] (iii) an antigenic polypeptide of respiratory syncytial virus (RSV).

[00462] For example, the immunogenic composition comprises:

[00463] (i) a self-replicating RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00464] (ii) a self-replicating RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00465] (iii) an antigenic polypeptide of respiratory syncytial virus (RSV).

[00466] In another example, the immunogenic composition comprises:

[00467] (i) a self-replicating RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element;

[00468] (ii) a self-replicating RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00469] (iii) an influenza antigenic polypeptide.

[00470] In another example, the immunogenic composition comprises:

[00471] (i) a self-replicating RNA comprising a sequence Petition 870260001818, dated 08 / 01 / 2026, page 50 / 357 46 / 291 nucleotides encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element;

[00472] (ii) a self-replicating RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00473] (iii) an influenza antigenic polypeptide.

[00474] In another example, the immunogenic composition comprises:

[00475] (i) a self-replicating RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00476] (ii) a self-replicating RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00477] (iii) an antigenic polypeptide of respiratory syncytial virus (RSV).

[00478] For example, the immunogenic composition comprises:

[00479] (i) a self-replicating RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operatively linked to a regulatory element;

[00480] (ii) a self-replicating RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to an element Petition 870260001818, dated 08 / 01 / 2026, page 51 / 357 47 / 291 regulator; and

[00481] (iii) an influenza antigenic polypeptide.

[00482] In another example, the immunogenic composition comprises:

[00483] (i) a self-replicating RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00484] (ii) a self-replicating RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00485] (iii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00486] In another example, the immunogenic composition comprises:

[00487] (i) a self-replicating RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00488] (ii) a self-replicating RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00489] (iii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00490] In another example, the immunogenic composition comprises:

[00491] (i) a self-replicating RNA comprising a sequence Petition 870260001818, dated 08 / 01 / 2026, page 52 / 357 48 / 291 nucleotides encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operatively linked to a regulatory element;

[00492] (ii) a self-replicating RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and

[00493] (iii) an antigenic polypeptide of influenza.

[00494] In one example, an immunogenic composition comprises multiple self-replicating multicistronic RNAs, wherein each self-replicating multicistronic RNA encodes a polypeptide of an antigen of interest. In another example, an immunogenic composition of disclosure comprises a plurality of self-replicating monocistronic RNAs, wherein each self-replicating RNA encodes different polypeptide sequences. For example, one self-replicating RNA encodes a polypeptide of an antigen of interest and a different self-replicating RNA encodes a different polypeptide of an antigen of interest.

[00495] In one example of the present description, the immunogenic composition comprises multiple polypeptide antigens, wherein each polypeptide is a different antigen of interest. In another embodiment, the polypeptide different from an antigen of interest may be from the same virus. For example, different polypeptides may originate from a respiratory syncytial virus (RSV), a severe acute respiratory syndrome coronavirus (SARS-CoV-2), or influenza.

[00496] For example, the immunogenic composition comprises:

[00497] (i) a polynucleotide comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nu sequence Petition 870260001818, dated 08 / 01 / 2026, page 53 / 357 49 / 291 nucleotides are operationally linked to a regulatory element;

[00498] (ii) an influenza antigenic polypeptide; and

[00499] (iii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00500] For example, the immunogenic composition comprises:

[00501] (i) a polynucleotide comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00502] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and

[00503] (iii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00504] For example, the immunogenic composition comprises:

[00505] (i) a polynucleotide comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), wherein the nucleotide sequence is operatively linked to a regulatory element;

[00506] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and

[00507] (iii) an antigenic polypeptide of influenza.

[00508] For example, the immunogenic composition comprises:

[00509] (i) a polynucleotide comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element;

[00510] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV); and

[00511] (iii) an additional polypeptide from a respiratory syncytial virus (RSV). Petition 870260001818, dated 08 / 01 / 2026, page 54 / 357 50 / 291

[00512] For example, the immunogenic composition comprises:

[00513] (i) a polynucleotide comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00514] (ii) an influenza antigenic polypeptide; and

[00515] (iii) an additional influenza antigenic polypeptide.

[00516] For example, the immunogenic composition comprises:

[00517] (i) a polynucleotide comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element;

[00518] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and

[00519] (iii) an additional antigenic polypeptide from a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00520] For example, the immunogenic composition comprises:

[00521] (i) an RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element;

[00522] (ii) an influenza antigenic polypeptide; and

[00523] (iii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00524] For example, the immunogenic composition comprises:

[00525] (i) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00526] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and Petition 870260001818, dated 08 / 01 / 2026, page 55 / 357 51 / 291

[00527] (iii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00528] For example, the immunogenic composition comprises:

[00529] (i) an RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), wherein the nucleotide sequence is operatively linked to a regulatory element;

[00530] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and

[00531] (iii) an antigenic polypeptide of influenza.

[00532] For example, the immunogenic composition comprises:

[00533] (i) an RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), wherein the nucleotide sequence is operatively linked to a regulatory element;

[00534] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV); and

[00535] (iii) an additional polypeptide from a respiratory syncytial virus (RSV).

[00536] For example, the immunogenic composition comprises:

[00537] (i) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00538] (ii) an influenza antigenic polypeptide; and

[00539] (iii) an additional influenza antigenic polypeptide.

[00540] For example, the immunogenic composition comprises:

[00541] (i) an RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; Petition 870260001818, dated 08 / 01 / 2026, page 56 / 357 52 / 291

[00542] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and

[00543] (iii) an additional antigenic polypeptide from a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00544] For example, the immunogenic composition comprises:

[00545] (i) a cRNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element;

[00546] (ii) an influenza antigenic polypeptide; and

[00547] (iii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00548] For example, the immunogenic composition comprises:

[00549] (i) a cRNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00550] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and

[00551] (iii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00552] For example, the immunogenic composition comprises:

[00553] (i) a cRNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element;

[00554] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and

[00555] (iii) an influenza antigenic polypeptide.

[00556] For example, the immunogenic composition comprises:

[00557] (i) a cRNA comprising a sequence of nucleotides Petition 870260001818, dated 08 / 01 / 2026, page 57 / 357 53 / 291 deos that encodes an antigen of a respiratory syncytial virus (RSV), in which the nucleotide sequence is operatively linked to a regulatory element;

[00558] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV); and

[00559] (iii) an additional polypeptide from a respiratory syncytial virus (RSV).

[00560] For example, the immunogenic composition comprises:

[00561] (i) a cRNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00562] (ii) an influenza antigenic polypeptide; and

[00563] (iii) an additional influenza antigenic polypeptide.

[00564] For example, the immunogenic composition comprises:

[00565] (i) a cRNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element;

[00566] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and

[00567] (iii) an additional antigenic polypeptide from a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00568] For example, the immunogenic composition comprises:

[00569] (i) a self-replicating RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operatively linked to a regulatory element;

[00570] (ii) an influenza antigenic polypeptide; and

[00571] (iii) an antigenic polypeptide of a respiratory syncytial virus Petition 870260001818, dated 08 / 01 / 2026, page 58 / 357 54 / 291 thorium (RSV).

[00572] For example, the immunogenic composition comprises:

[00573] (i) a self-replicating RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element;

[00574] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and

[00575] (iii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00576] For example, the immunogenic composition comprises:

[00577] (i) a self-replicating RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), wherein the nucleotide sequence is operatively linked to a regulatory element;

[00578] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and

[00579] (iii) an influenza antigenic polypeptide.

[00580] For example, the immunogenic composition comprises:

[00581] (i) a self-replicating RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), wherein the nucleotide sequence is operatively linked to a regulatory element;

[00582] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV); and

[00583] (iii) an additional polypeptide from a respiratory syncytial virus (RSV).

[00584] For example, the immunogenic composition comprises:

[00585] (i) a self-replicating RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the sequence Petition 870260001818, dated 08 / 01 / 2026, page 59 / 357 55 / 291 nucleotide chain is operationally linked to a regulatory element;

[00586] (ii) an influenza antigenic polypeptide; and

[00587] (iii) an additional influenza antigenic polypeptide.

[00588] For example, the immunogenic composition comprises:

[00589] (i) a self-replicating RNA comprising a nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operatively linked to a regulatory element;

[00590] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and

[00591] (iii) an additional antigenic polypeptide from a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00592] In one example, the compositions described in this document also include an adjuvant.

[00593] In one example of the disclosure, a protein antigen is formulated with an adjuvant.

[00594] In one example, the adjuvant is selected from the group consisting of Freund's adjuvant, incomplete Freund's adjuvants, aluminum phosphate, aluminum hydroxide, GMCSP, BCG, MDP compounds such as thur-MDP and nor-MDP, CGP (MTP-PE), lipid A, lipid A monophosphorylated (MPL), RIBI, MPL, trehalose dimycolate (TDM), Novasomes®, QS21, Quil A (and derivatives and components thereof), calcium phosphate, calcium hydroxide, zinc hydroxide, MHC antigens, PolyI:C, MF59, glycolipid analogs, octadecyl esters of an amino acid, muramyl dipeptides, polyphosphazene, lipoproteins, ISCOM matrix, DC-Chol, ODA, cytokines and other adjuvants and derivatives thereof. In another example, the adjuvant is MF59.

[00595] In one example, the effect of an immunogenic composition Petition 870260001818, dated 08 / 01 / 2026, page 60 / 357 The effect of compound 56 / 291 described in this document, in the treatment, prevention or delay of the progression of a disease or disorder, is potentiated in the presence of an adjuvant such as MF59, when compared to the effect of an immunogenic composition described in this document without an adjuvant.

[00596] In one example, the effect of an immunogenic composition described in this document, in the treatment, prevention or delay of the progression of an infection by SARS-CoV-2, COVID-19, influenza and / or respiratory syncytial virus (RSV), is potentiated in the presence of an adjuvant such as MF59, when compared to the effect of an immunogenic composition described in this document without adjuvant.

[00597] In one example, the effect of an immunogenic composition described in this document, in the treatment, prevention or delay of the progression of pneumonia, sepsis or acute respiratory distress syndrome in an individual with COVID-19, is potentiated in the presence of an adjuvant such as MF59, when compared to the effect of an immunogenic composition described in this document without adjuvant.

[00598] In one example, the effect of an immunogenic composition described in this document, in the treatment, prevention or delay of the progression of an influenza infection, is potentiated in the presence of an adjuvant such as MF59, when compared to the effect of an immunogenic composition described in this document without adjuvant.

[00599] In one example, the effect of an immunogenic composition described in this document, in the treatment, prevention or delay of the progression of an RSV infection, is potentiated in the presence of an adjuvant such as MF59, when compared to the effect of an immunogenic composition described in this document without adjuvant.

[00600] In one example, the effect of an immunogenic composition Petition 870260001818, dated 08 / 01 / 2026, page 61 / 357 The effect of compound 57 / 291, described in this document, in inducing an immune response in an individual, is enhanced in the presence of an adjuvant such as MF59, when compared to the effect of an immunogenic composition described in this document without adjuvant.

[00601] In one example, the presence of an adjuvant such as MF59 in an immunogenic composition described in this document increases the induction of the immune response of the composition by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 100%, at least about 200%, at least about 300%, by less approximately 400%, at least approximately 500% or more when compared to the effect of an immunogenic composition described in this document without an adjuvant such as MF59.

[00602] In one example, the adjuvant is administered at the same time as an immunogenic composition of the description. In another example, the adjuvant is administered sequentially, before or following the administration of an immunogenic composition of the present invention.

[00603] In one example, a composition described in this document further comprises an additional polypeptide selected from the group consisting of:

[00604] (i) one or more antigens;

[00605] (ii) one or more immunopotentiating agents;

[00606] (iii) one or more chemoattractants; and / or Petition 870260001818, dated 08 / 01 / 2026, page 62 / 357 58 / 291

[00607] (iv) one or more targeting molecules.

[00608] In one example, the nucleotide sequence is operationally linked to a regulatory element selected from the group consisting of a promoter, optionally a subgenomic promoter (SG), an internal ribosome entry site (IRES), and a Kozak consensus sequence or a combination thereof. In one example, the regulatory element is an SG promoter.

[00609] For example, the immunogenic composition polynucleotide comprises a nucleotide sequence that encodes an antigen operationally bound to a selected regulatory element of an SG promoter, and IRES and / or a Kozak consensus sequence.

[00610] In another example, the RNA of the immunogenic composition comprises a nucleotide sequence that encodes an antigen operatively bound to a selected regulatory element of an SG promoter, and IRES and / or a Kozak consensus sequence.

[00611] In another example, the cRNA of the immunogenic composition comprises a nucleotide sequence that encodes an antigen operatively bound to a selected regulatory element of an SG promoter, and IRES and / or a Kozak consensus sequence.

[00612] In another example, the self-replicating RNA of the immunogenic composition comprises a nucleotide sequence that encodes an antigen operationally bound to a regulatory element selected from an SG promoter, and IRES and / or a Kozak consensus sequence.

[00613] Thus, the present disclosure offers an immunogenic composition comprising:

[00614] (i) a polynucleotide comprising: a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV); and b) a second nucleotide sequence encoding an influenza antigen, operatively linked to a Petition 870260001818, dated 08 / 01 / 2026, page 63 / 357 59 / 291 selected regulatory element from the group consisting of an SG promoter and an IRES; and

[00615] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00616] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV); and b) a second nucleotide sequence encoding an influenza antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00617] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen; and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00618] In another example, the present description provides an immunogenic composition comprising:

[00619] (i) a polynucleotide comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and b) a second nucleotide sequence encoding an influenza antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and

[00620] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00621] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and b) a second nucleotide sequence that co Petition 870260001818, dated 08 / 01 / 2026, page 64 / 357 60 / 291 identifies an influenza antigen, operatively linked to a selected regulatory element from the group consisting of an SG promoter and an IRES.

[00622] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), operationally linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00623] In another example, the present description provides an immunogenic composition comprising:

[00624] (i) a polynucleotide comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and

[00625] (ii) an influenza antigenic polypeptide.

[00626] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00627] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV); and b) a second Petition 870260001818, dated 08 / 01 / 2026, page 65 / 357 61 / 291 of the nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), operationally linked to a selected regulatory element from the group consisting of an SG promoter and an IRES.

[00628] Thus, the present description also provides an immunogenic composition comprising:

[00629] (i) an RNA comprising: a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV); and b) a second nucleotide sequence encoding an influenza antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and

[00630] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00631] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV); and b) a second nucleotide sequence encoding an influenza antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00632] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen; and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00633] In another example, the present description provides an immunogenic composition comprising:

[00634] (i) an RNA comprising: a) a first nucleotide sequence encoding an antigen of a coronavirus of the syndrome Petition 870260001818, dated 08 / 01 / 2026, page 66 / 357 62 / 291 severe acute respiratory infection (SARS-CoV-2); and b) a second nucleotide sequence encoding an influenza antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and

[00635] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00636] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and b) a second nucleotide sequence encoding an influenza antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00637] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), operationally linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00638] In another example, the present description provides an immunogenic composition comprising:

[00639] (i) an RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and

[00640] (ii) an influenza antigenic polypeptide.

[00641] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence that codes for an antigen of a severe acute respiratory syndrome coronavirus (SARS). 63 / 291 CoV-2); and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, operatively linked to a regulatory element selected from the cluster consisting of an SG promoter and an IRES.

[00642] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV); and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00643] Thus, the present description also provides an immunogenic composition comprising:

[00644] (i) a cRNA comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen; and b) a second nucleotide sequence encoding an influenza antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and

[00645] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00646] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV); and b) a second nucleotide sequence encoding an influenza antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00647] In one example, cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence that codes for an influenza antigen; and b) a second nucleotide sequence that co Petition 870260001818, dated 08 / 01 / 2026, page 68 / 357 64 / 291 identifies a respiratory syncytial virus (RSV) antigen, operatively linked to a selected regulatory element from the group consisting of an SG promoter and an IRES.

[00648] In another example, the present description provides an immunogenic composition comprising:

[00649] (i) a cRNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and b) a second nucleotide sequence encoding an influenza antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and

[00650] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00651] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and b) a second nucleotide sequence encoding an influenza antigen, operationally linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00652] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), operationally linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00653] In another example, the present description provides an immunogenic composition comprising:

[00654] (i) a cRNA comprising: a) a first nucleotide sequence encoding an antigen of a coronavirus from syn Petition 870260001818, dated 08 / 01 / 2026, page 69 / 357 65 / 291 severe acute respiratory syndrome (SARS-CoV-2); and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and

[00655] (ii) an influenza antigenic polypeptide.

[00656] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00657] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV); and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00658] Thus, the present description also provides an immunogenic composition comprising:

[00659] (i) a self-replicating RNA comprising: a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV); and b) a second nucleotide sequence encoding an influenza antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and

[00660] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2). Petition 870260001818, dated 08 / 01 / 2026, page 70 / 357 66 / 291

[00661] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV); and b) a second nucleotide sequence encoding an influenza antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00662] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen; and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00663] In another example, the present description provides an immunogenic composition comprising:

[00664] (i) a self-replicating RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and b) a second nucleotide sequence encoding an influenza antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and

[00665] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00666] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and b) a second nucleotide sequence encoding an influenza antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00667] In one example, self-replicating RNA comprises, in Petition 870260001818, dated 08 / 01 / 2026, page 71 / 357 67 / 291 5' to 3' order: a) a first nucleotide sequence encoding an influenza antigen; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), operationally linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00668] In another example, the present description provides an immunogenic composition comprising:

[00669] (i) a self-replicating RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and

[00670] (ii) an influenza antigenic polypeptide.

[00671] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2); and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00672] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV); and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES. Petition 870260001818, dated 08 / 01 / 2026, page 72 / 357 68 / 291

[00673] This disclosure also offers an immunogenic composition comprising

[00674] (i) a polynucleotide comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and

[00675] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00676] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a first respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00677] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding a first respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES. Petition 870260001818, dated 08 / 01 / 2026, page 73 / 357 69 / 291

[00678] In another example, the immunogenic composition comprises:

[00679] (i) a polynucleotide comprising: a) a first nucleotide sequence encoding a SARS-CoV-2 antigen operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and

[00680] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00681] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a first antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operationally linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding an influenza antigen, operationally linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00682] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and b) a second nucleotide sequence encoding a first antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element. Petition 870260001818, dated 08 / 01 / 2026, page 74 / 357 70 / 291 selected from the group consisting of an SG promoter and an IRES.

[00683] In another example, the immunogenic composition comprises:

[00684] (i) a polynucleotide comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operationally linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operationally linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and

[00685] (ii) an influenza antigenic polypeptide.

[00686] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a first antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00687] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleolus sequence Petition 870260001818, dated 08 / 01 / 2026, page 75 / 357 71 / 291 typs encoding a first antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a selected regulatory element from the group consisting of an SG promoter and an IRES.

[00688] The present description also provides an immunogenic composition comprising

[00689] (i) an RNA comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and

[00690] (ii) an antigenic polypeptide of SARS-CoV-2.

[00691] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a first respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00692] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, functionally linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and b) a second nucleotide sequence encoding a first antigen. Petition 870260001818, dated 08 / 01 / 2026, page 76 / 357 72 / 291 of respiratory syncytial virus (RSV) functionally linked to a selected regulatory element from the group consisting of an SG promoter and an IRES.

[00693] In another example, the immunogenic composition comprises:

[00694] (i) an RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and

[00695] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00696] In one example, RNA comprises, on the order of 5' to 3': a) a first nucleotide sequence encoding a first antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00697] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, actively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and b) a Petition 870260001818, dated 01 / 08 / 2026, p. 77 / 357 73 / 291 second nucleotide sequence encoding a first antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV2) actively bound to a selected regulatory element from the cluster consisting of an SG promoter and an IRES.

[00698] In another example, the immunogenic composition comprises:

[00699] (i) an RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and

[00700] (ii) an influenza antigenic polypeptide.

[00701] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a first antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00702] In one example, RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of a Petition 870260001818, dated 08 / 01 / 2026, page 78 / 357 74 / 291 Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding a first antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00703] The present description also provides an immunogenic composition comprising

[00704] (i) a cRNA comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and

[00705] (ii) an antigenic polypeptide of SARS-CoV-2.

[00706] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a first respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00707] In one example, cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a regulatory element selected from the group consisting of a consensus sequence of Petition 870260001818, dated 08 / 01 / 2026, page 79 / 357 75 / 291 Kozak, an IRES, an SG promoter, and combinations thereof; and b) a second nucleotide sequence encoding a first respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00708] In another example, the immunogenic composition comprises:

[00709] (i) a cRNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and

[00710] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00711] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a first antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00712] In one example, cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence that encodes an influenza antigen, operatively linked to a regulatory element Petition 870260001818, dated 08 / 01 / 2026, page 80 / 357 76 / 291 selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding a first antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00713] In another example, the immunogenic composition comprises:

[00714] (i) a cRNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and

[00715] (ii) an influenza antigenic polypeptide.

[00716] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a first antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00717] In one example, cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence that codes for an antigen Petition 870260001818, dated 08 / 01 / 2026, page 81 / 357 77 / 291 number of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding a first antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00718] The present description also provides an immunogenic composition comprising

[00719] (i) a self-replicating RNA comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and

[00720] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00721] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a first respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00722] In one example, self-replicating RNA comprises, in Petition 870260001818, dated 08 / 01 / 2026, page 82 / 357 78 / 291 5' to 3' order: a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding a first respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00723] In another example, the immunogenic composition comprises:

[00724] (i) a self-replicating RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and

[00725] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00726] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a first antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and Petition 870260001818, dated 08 / 01 / 2026, page 83 / 357 79 / 291 one IRES.

[00727] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding a first antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00728] In another example, the immunogenic composition comprises:

[00729] (i) a self-replicating RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES; and

[00730] (ii) an influenza antigenic polypeptide.

[00731] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a first antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter, and combinations thereof; and b) a second nucleotide sequence encoding Petition 870260001818, dated 08 / 01 / 2026, page 84 / 357 80 / 291 is an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00732] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of a Kozak consensus sequence, an IRES, an SG promoter and combinations thereof; and b) a second nucleotide sequence encoding a first antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00733] ​​This disclosure provides an immunogenic composition comprising:

[00734] (i) a polynucleotide comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00735] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00736] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group that Petition 870260001818, dated 08 / 01 / 2026, page 85 / 357 81 / 291 consists of an SG promoter and an IRES.

[00737] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00738] For example, the immunogenic composition comprises:

[00739] (i) a polynucleotide comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operationally linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an influenza antigen, operationally linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00740] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00741] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operationally linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an influenza antigen, operationally linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00742] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operationally linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an antigen of an acute respiratory syndrome coronavirus. Petition 870260001818, dated 08 / 01 / 2026, page 86 / 357 82 / 291 of severe (SARS-CoV-2) operationally linked to a selected regulatory element from the group consisting of an SG promoter and an IRES.

[00743] For example, the immunogenic composition comprises:

[00744] (i) a polynucleotide comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00745] (ii) an influenza antigenic polypeptide.

[00746] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00747] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operationally linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operationally linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00748] In another example, the present description provides an immunogenic composition comprising: Petition 870260001818, dated 08 / 01 / 2026, page 87 / 357 83 / 291

[00749] (i) an RNA comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00750] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00751] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00752] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00753] For example, the immunogenic composition comprises:

[00754] (i) an RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and Petition 870260001818, dated 08 / 01 / 2026, page 88 / 357 84 / 291

[00755] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00756] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00757] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00758] For example, the immunogenic composition comprises:

[00759] (i) an RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00760] (ii) an influenza antigenic polypeptide.

[00761] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an Petition 870260001818, dated 08 / 01 / 2026, page 89 / 357 85 / 291 tygene of a respiratory syncytial virus (RSV), operatively linked to a selected regulatory element from the group consisting of an SG promoter and an IRES.

[00762] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00763] In another example, the present description provides an immunogenic composition comprising:

[00764] (i) a cRNA comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00765] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00766] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00767] In one example, cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence that codes for an antigen Petition 870260001818, dated 08 / 01 / 2026, page 90 / 357 86 / 291 influenza antigen, operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00768] For example, the immunogenic composition comprises:

[00769] (i) a cRNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00770] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00771] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00772] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00773] For example, the immunogenic composition comprises: Petition 870260001818, dated 08 / 01 / 2026, page 91 / 357 87 / 291

[00774] (i) a cRNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00775] (ii) an influenza antigenic polypeptide.

[00776] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00777] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00778] In another example, the present description provides an immunogenic composition comprising:

[00779] (i) a self-replicating RNA comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence that Petition 870260001818, dated 08 / 01 / 2026, page 92 / 357 88 / 291 encodes an influenza antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00780] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00781] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00782] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00783] For example, the immunogenic composition comprises:

[00784] (i) a self-replicating RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00785] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00786] In one example, self-replicating RNA comprises, in Petition 870260001818, dated 08 / 01 / 2026, page 93 / 357 89 / 291 5' to 3' order: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00787] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00788] For example, the immunogenic composition comprises:

[00789] (i) a self-replicating RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00790] (ii) an influenza antigenic polypeptide.

[00791] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence that Petition 870260001818, dated 08 / 01 / 2026, page 94 / 357 90 / 291 encodes a respiratory syncytial virus (RSV) antigen, operatively linked to a selected regulatory element from the group consisting of an SG promoter and an IRES.

[00792] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a Kozak consensus sequence; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00793] This disclosure provides an immunogenic composition comprising:

[00794] (i) a polynucleotide comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00795] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00796] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00797] In one example, the polynucleotide comprises, in order Petition 870260001818, dated 08 / 01 / 2026, page 95 / 357 91 / 291 from 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00798] For example, the immunogenic composition comprises:

[00799] (i) a polynucleotide comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00800] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00801] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00802] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked Petition 870260001818, dated 08 / 01 / 2026, page 96 / 357 92 / 291 refers to a selected regulatory element from the group consisting of an SG promoter and an IRES.

[00803] For example, the immunogenic composition comprises:

[00804] (i) a polynucleotide comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00805] (ii) an influenza antigenic polypeptide.

[00806] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operationally linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operationally linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00807] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00808] In another example, the present description provides an immunogenic composition comprising: Petition 870260001818, dated 08 / 01 / 2026, page 97 / 357 93 / 291

[00809] (i) an RNA comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00810] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00811] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00812] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00813] For example, the immunogenic composition comprises:

[00814] (i) an RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group Petition 870260001818, dated 08 / 01 / 2026, page 98 / 357 94 / 291 which consists of an SG promoter and an IRES, and

[00815] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00816] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00817] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00818] For example, the immunogenic composition comprises:

[00819] (i) an RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00820] (ii) an influenza antigenic polypeptide.

[00821] In one example, RNA comprises, on the order of 5' to Petition 870260001818, dated 08 / 01 / 2026, page 99 / 357 95 / 291 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00822] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00823] In another example, the present description provides an immunogenic composition comprising:

[00824] (i) a cRNA comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00825] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00826] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a Kozak consensus sequence and an SG promoter; and b) a se Petition 870260001818, dated 08 / 01 / 2026, page 100 / 357 96 / 291 second nucleotide sequence that encodes an influenza antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00827] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00828] For example, the immunogenic composition comprises:

[00829] (i) a cRNA comprising: a) a first nucleotide sequence encoding a SARS-CoV-2 antigen operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00830] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00831] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00832] In one example, cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence that codes for an antigen Petition 870260001818, dated 08 / 01 / 2026, page 101 / 357 97 / 291 influenza antigen, operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00833] For example, the immunogenic composition comprises:

[00834] (i) a cRNA comprising: a) a first nucleotide sequence encoding a SARS-CoV-2 antigen operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00835] (ii) an influenza antigenic polypeptide.

[00836] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00837] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group Petition 870260001818, dated 08 / 01 / 2026, page 102 / 357 98 / 291 which consists of an SG promoter and an IRES.

[00838] In another example, the present description provides an immunogenic composition comprising:

[00839] (i) a self-replicating RNA comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00840] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00841] In one example, the self-replicating RNA comprises, in the 5' to 3' order: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00842] In one example, the self-replicating RNA comprises, in the 5' to 3' order: a) a first nucleotide sequence encoding an influenza antigen operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00843] For example, the immunogenic composition comprises:

[00844] (i) a self-replicating RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) linked to Petition 870260001818, dated 08 / 01 / 2026, page 103 / 357 99 / 291 operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00845] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00846] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00847] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00848] For example, the immunogenic composition comprises:

[00849] (i) a self-replicating RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of a pro Petition 870260001818, dated 08 / 01 / 2026, page 104 / 357 100 / 291 SG motor and an IRES, and

[00850] (ii) an influenza antigenic polypeptide.

[00851] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00852] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00853] This disclosure provides an immunogenic composition comprising:

[00854] (i) a polynucleotide comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00855] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00856] In one example, the polynucleotide comprises, in order Petition 870260001818, dated 08 / 01 / 2026, page 105 / 357 101 / 291 from 5' to 3': a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00857] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00858] For example, the immunogenic composition comprises:

[00859] (i) a polynucleotide comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00860] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00861] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operationally linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an influenza antigen, operationally linked to a regulatory element selected from the group consisting of an SG promoter and Petition 870260001818, dated 08 / 01 / 2026, page 106 / 357 102 / 291 one IRES.

[00862] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00863] For example, the immunogenic composition comprises:

[00864] (i) a polynucleotide comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00865] (ii) an influenza antigenic polypeptide.

[00866] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00867] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), linked in a way Petition 870260001818, dated 08 / 01 / 2026, page 107 / 357 103 / 291 operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00868] In another example, the present description provides an immunogenic composition comprising:

[00869] (i) an RNA comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00870] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00871] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00872] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES. Petition 870260001818, dated 08 / 01 / 2026, page 108 / 357 104 / 291

[00873] For example, the immunogenic composition comprises:

[00874] (i) an RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00875] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00876] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00877] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding a SARS-CoV-2 antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00878] For example, the immunogenic composition comprises:

[00879] (i) an RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an IRES; and b) a second sequence Petition 870260001818, dated 08 / 01 / 2026, page 109 / 357 105 / 291 nucleotide chain encoding a respiratory syncytial virus (RSV) antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00880] (ii) an influenza antigenic polypeptide.

[00881] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00882] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00883] In another example, the present description provides an immunogenic composition comprising:

[00884] (i) a cRNA comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00885] (ii) an antigenic polypeptide of a coronavirus from the syn Petition 870260001818, dated 08 / 01 / 2026, page 110 / 357 106 / 291 severe acute respiratory syndrome (SARS-CoV-2).

[00886] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00887] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00888] For example, the immunogenic composition comprises:

[00889] (i) a cRNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00890] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00891] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence that Petition 870260001818, dated 08 / 01 / 2026, page 111 / 357 107 / 291 encodes an influenza antigen, operatively linked to a selected regulatory element from the group consisting of an SG promoter and an IRES.

[00892] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00893] For example, the immunogenic composition comprises:

[00894] (i) a cRNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00895] (ii) an influenza antigenic polypeptide.

[00896] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00897] In one example, the cRNA comprises, on the order of 5' to Petition 870260001818, dated 08 / 01 / 2026, page 112 / 357 108 / 291 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00898] In another example, the present description provides an immunogenic composition comprising:

[00899] (i) a self-replicating RNA comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00900] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00901] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00902] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding a respiratory syncytial virus antigen. Petition 870260001818, dated 08 / 01 / 2026, page 113 / 357 109 / 291 respiratory (RSV) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00903] For example, the immunogenic composition comprises:

[00904] (i) a self-replicating RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an influenza antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00905] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00906] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00907] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to a Kozak consensus sequence and an SG promoter; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00908] For example, the immunogenic composition comprises:

[00909] (i) a self-replicating RNA comprising: a) a primary Petition 870260001818, dated 08 / 01 / 2026, page 114 / 357 110 / 291 ra nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00910] (ii) an influenza antigenic polypeptide.

[00911] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00912] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a Kozak consensus sequence and an IRES; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00913] This disclosure provides an immunogenic composition comprising:

[00914] (i) a polynucleotide comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen. Petition 870260001818, dated 08 / 01 / 2026, page 115 / 357 111 / 291 enza, operationally linked to a selected regulatory element of the group consisting of an SG promoter and an IRES, and

[00915] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00916] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00917] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, functionally linked to an SG promoter; and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen functionally linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00918] For example, the immunogenic composition comprises:

[00919] (i) a polynucleotide comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00920] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00921] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first sequence of nucleotides that codes Petition 870260001818, dated 08 / 01 / 2026, page 116 / 357 112 / 291 a SARS-CoV-2 antigen operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00922] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen functionally linked to an SG promoter; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV2) functionally linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00923] For example, the immunogenic composition comprises:

[00924] (i) a polynucleotide comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00925] (ii) an influenza antigenic polypeptide.

[00926] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00927] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first sequence of nucleotides that codes Petition 870260001818, dated 08 / 01 / 2026, page 117 / 357 113 / 291 a respiratory syncytial virus (RSV) antigen functionally linked to an SG promoter; and b) a second nucleotide sequence encoding a severe acute respiratory syndrome coronavirus (SARS-CoV-2) antigen functionally linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00928] In another example, the present description provides an immunogenic composition comprising:

[00929] (i) an RNA comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00930] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00931] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00932] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, functionally linked to an SG promoter; and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen functionally linked to a regulatory element selected from the group consisting of an SG promoter and an IRES. Petition 870260001818, dated 08 / 01 / 2026, page 118 / 357 114 / 291

[00933] For example, the immunogenic composition comprises:

[00934] (i) an RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00935] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00936] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00937] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, functionally linked to an SG promoter; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) functionally linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00938] For example, the immunogenic composition comprises:

[00939] (i) an RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked Petition 870260001818, dated 08 / 01 / 2026, page 119 / 357 115 / 291 specifically to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00940] (ii) an influenza antigenic polypeptide.

[00941] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00942] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00943] In another example, the present description provides an immunogenic composition comprising:

[00944] (i) a cRNA comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00945] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00946] In one example, the cRNA comprises, on the order of 5' to Petition 870260001818, dated 08 / 01 / 2026, page 120 / 357 116 / 291 3': a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00947] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to an SG promoter; and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00948] For example, the immunogenic composition comprises:

[00949] (i) a cRNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00950] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00951] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES. Petition 870260001818, dated 08 / 01 / 2026, page 121 / 357 117 / 291

[00952] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00953] For example, the immunogenic composition comprises:

[00954] (i) a cRNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00955] (ii) an influenza antigenic polypeptide.

[00956] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00957] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a re element. Petition 870260001818, dated 08 / 01 / 2026, page 122 / 357 118 / 291 selected glycatory from the group consisting of an SG promoter and an IRES.

[00958] In another example, the present description provides an immunogenic composition comprising:

[00959] (i) a self-replicating RNA comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00960] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00961] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00962] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, functionally linked to an SG promoter; and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen functionally linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00963] For example, the immunogenic composition comprises:

[00964] (i) a self-replicating RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) that is openly bound Petition 870260001818, dated 08 / 01 / 2026, page 123 / 357 119 / 291 operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00965] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00966] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00967] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00968] For example, the immunogenic composition comprises:

[00969] (i) a self-replicating RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00970] (ii) an influenza antigenic polypeptide. Petition 870260001818, dated 08 / 01 / 2026, page 124 / 357 120 / 291

[00971] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00972] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to an SG promoter; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00973] This disclosure provides an immunogenic composition comprising:

[00974] (i) a polynucleotide comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00975] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00976] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively bound to an IRES; and b) a second nucleotide sequence that Petition 870260001818, dated 08 / 01 / 2026, page 125 / 357 121 / 291 encodes an influenza antigen, operatively linked to a selected regulatory element from the group consisting of an SG promoter and an IRES.

[00977] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to an IRES; and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00978] For example, the immunogenic composition comprises:

[00979] (i) a polynucleotide comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00980] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00981] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operationally linked to an IRES; and b) a second nucleotide sequence encoding an influenza antigen, operationally linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00982] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operationally linked to an IRES; and b) a Petition 870260001818, dated 08 / 01 / 2026, page 126 / 357 122 / 291 second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operationally linked to a selected regulatory element from the group consisting of an SG promoter and an IRES.

[00983] For example, the immunogenic composition comprises:

[00984] (i) a polynucleotide comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to an IRES; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00985] (ii) an influenza antigenic polypeptide.

[00986] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operationally linked to an IRES; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operationally linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00987] In one example, the polynucleotide comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to an IRES; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00988] In another example, the present description provides a with Petition 870260001818, dated 08 / 01 / 2026, page 127 / 357 123 / 291 immunogenic position comprising:

[00989] (i) an RNA comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and

[00990] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2).

[00991] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00992] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to an IRES; and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00993] For example, the immunogenic composition comprises:

[00994] (i) an RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and Petition 870260001818, dated 08 / 01 / 2026, page 128 / 357 124 / 291

[00995] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV).

[00996] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operationally linked to an IRES; and b) a second nucleotide sequence encoding an influenza antigen, operationally linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00997] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to an IRES; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES.

[00998] For example, the immunogenic composition comprises:

[00999] (i) an RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to an IRES; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and [001000] (ii) an antigenic polypeptide of influenza. [001001] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operationally linked to an IRES; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus. Petition 870260001818, dated 08 / 01 / 2026, page 129 / 357 125 / 291 respiratory (RSV), operationally linked to a selected regulatory element from the group consisting of an SG promoter and an IRES. [001002] In one example, the RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to an IRES; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES. [001003] In another example, the present description provides an immunogenic composition comprising: [001004] (i) a cRNA comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and [001005] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2). [001006] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES. [001007] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to an IRES; and b) a second nucleotide sequence encoding a viral antigen. Petition 870260001818, dated 08 / 01 / 2026, page 130 / 357 126 / 291 respiratory syncytial (RSV) operatively linked to a selected regulatory element from the group consisting of an SG promoter and an IRES. [001008] For example, the immunogenic composition comprises: [001009] (i) a cRNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and [001010] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV). [001011] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES. [001012] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to an IRES; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES. [001013] For example, the immunogenic composition comprises: [001014] (i) a cRNA comprising: a) a first nucleotide sequence encoding an antigen of a coronavirus of the synPetition 870260001818, of 08 / 01 / 2026, page 131 / 357 127 / 291 severe acute respiratory syndrome (SARS-CoV-2) operatively linked to an IRES; and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and [001015] (ii) an antigenic polypeptide of influenza. [001016] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to an IRES; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES. [001017] In one example, the cRNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to an IRES; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES. [001018] In another example, the present description provides an immunogenic composition comprising: [001019] (i) a self-replicating RNA comprising: a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and [001020] (ii) an antigenic polypeptide of a severe acute respiratory syndrome coronavirus (SARS-CoV-2). Petition 870260001818, dated 08 / 01 / 2026, page 132 / 357 128 / 291 [001021] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES. [001022] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to an IRES; and b) a second nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES. [001023] For example, the immunogenic composition comprises: [001024] (i) a self-replicating RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to an IRES; and b) a second nucleotide sequence encoding an influenza antigen operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and [001025] (ii) an antigenic polypeptide of a respiratory syncytial virus (RSV). [001026] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operationally linked to an IRES; and b) a second nucleotide sequence encoding an influenza antigen, operationally linked to a regulatory element selected from Petition 870260001818, dated 08 / 01 / 2026, page 133 / 357 129 / 291 group consisting of an SG promoter and an IRES. [001027] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an influenza antigen, operatively linked to an IRES; and b) a second nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES. [001028] For example, the immunogenic composition comprises: [001029] (i) a self-replicating RNA comprising: a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to an IRES; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV) operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES, and [001030] (ii) an influenza antigenic polypeptide. [001031] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a severe acute respiratory syndrome coronavirus (SARS-CoV-2) operatively linked to an IRES; and b) a second nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to a regulatory element selected from the group consisting of an SG promoter and an IRES. [001032] In one example, the self-replicating RNA comprises, in the order of 5' to 3': a) a first nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), operatively linked to an IRES; and b) a second nucleotide sequence encoding an antigen of a respiratory syndrome coronavirus. Petition 870260001818, dated 08 / 01 / 2026, page 134 / 357 130 / 291 severe acute respiratory infection (SARS-CoV-2) operatively linked to a selected regulatory element from the group consisting of an SG promoter and an IRES. [001033] In one example, the disclosure additionally provides an immunogenic composition comprising: [001034] (i) an F protein of the RSV; and [001035] (ii) a sa-mRNA encoding an influenza HA. [001036] In one example, the disclosure additionally provides an immunogenic composition comprising: [001037] (i) an F protein of the RSV; and [001038] (ii) a sa-mRNA encoding an influenza HA and NA. [001039] In one example, the disclosure additionally provides an immunogenic composition comprising: [001040] (i) an F protein of the RSV; and [001041] (ii) a plurality of sa-mRNAs, each sa-mRNA encoding an influenza HA. [001042] In one example, the disclosure additionally provides an immunogenic composition comprising: [001043] (i) an F protein of the RSV; and [001044] (ii) a plurality of sa-mRNAs, each sa-mRNA encoding an influenza HA and NA. [001045] In one example, the disclosure additionally provides an immunogenic composition comprising: [001046] (i) an F protein of the RSV; and [001047] (ii) three or more sa-mRNAs, each sa-mRNA encoding an influenza HA. [001048] In one example, the disclosure additionally provides an immunogenic composition comprising: [001049] (i) an F protein of the RSV; and [001050] (ii) three or more sa-mRNAs, each sa-mRNA encoding Petition 870260001818, dated 08 / 01 / 2026, page 135 / 357 131 / 291 one HA and one NA of influenza. [001051] (i) an F protein of the RSV; and [001052] (ii) four or more sa-mRNAs, each sa-mRNA encoding an influenza HA. [001053] In one example, the disclosure additionally provides an immunogenic composition comprising: [001054] (i) an F protein of the RSV; and [001055] (ii) four or more sa-mRNAs, each sa-mRNA encoding an influenza HA and NA. [001056] In some examples, such as when multiple antigen-coding sequences are included in a single sa-mRNA, the first nucleotide sequence is operationally linked to an SG promoter and the second nucleotide sequence is also operationally linked to an SG promoter. [001057] In one example, the SG promoter is a native SG promoter. For example, a native SG promoter is a native promoter of the RNA virus from which it is derived and / or based (e.g., an alphavirus). In one example, the native SG promoter is a native alphavirus SG promoter. [001058] In some examples, the SG promoter is encoded by a sequence comprising or consisting of SEQ ID NO: 32. [001059] In one example, the SG promoter is either a minimal SG promoter or an extended SG promoter. [001060] In one example, the SG promoter is a minimal SG promoter. In one example, the native SG promoter is a minimal SG promoter. For example, the minimal SG promoter is the minimum sequence required for transcription initiation. In one example, the minimal native SG promoter is 49 nucleotides long. In one example, the minimal SG promoter is 49 nucleotides long. In one example, the minimal native SG promoter is encoded by a sequence that Petition 870260001818, dated 08 / 01 / 2026, page 136 / 357 132 / 291 comprises or consists of a sequence set at SEQ ID NO: 13. In one example, the minimum SG promoter is encoded by a sequence that comprises or consists of a sequence set at SEQ ID NO: 13. [001061] In one example, the SG promoter is an extended SG promoter. In one example, the native SG promoter is an extended SG promoter. For example, the extended SG promoter is extended at the 5' end with nucleotides that occur in a sequence encoding a non-structural protein (e.g., NSP4) of the RNA virus (e.g., an alphavirus). In one example, the extended SG promoter is extended at the 5' end with nucleotides that occur in a sequence encoding an alphavirus NSP4. The addition of nucleotides to the 5' end of the SG promoter sequence did not interfere with the expression of the non-structural protein and viral replicase, e.g., alphavirus NSP4. [001062] In one example, the SG promoter is extended at the 5' end by 51 or fewer nucleotides occurring in a sequence encoding a non-structural protein (e.g., an alphavirus NSP4). In one example, the extended SG promoter is a minimal SG promoter extended at the 5' end by no more than 51 nucleotides occurring in a sequence encoding a non-structural protein (e.g., an alphavirus NSP4). In one example, the extended SG promoter is encoded by a sequence comprising or consisting of a sequence established at SEQ ID NO: 13, extended at the 5' end by no more than 51 nucleotides, present in a sequence encoding a non-structural protein (e.g., an alphavirus NSP4). For example, the extended SG promoter is no more than 100 nucleotides long. In one example, the extended SG promoter is encoded by a sequence comprising or consisting of nucleotides 2 to 101 of SEQ ID NO: Petition 870260001818, dated 08 / 01 / 2026, page 137 / 357 133 / 291 17. [001063] In one example, the SG promoter is extended at the 5' end by about 5 to about 20 nucleotides, for example, by about 5 nucleotides, or about 10 nucleotides, or about 12, or about 15 nucleotides, or about 20 nucleotides, occurring in a sequence encoding a non-structural protein (e.g., an alphavirus NSP4). In another example, the SG promoter is extended at the 5' end by about 20 to about 35 nucleotides, for example, by about 25 nucleotides or about 27 nucleotides, or about 30 nucleotides, or about 35 nucleotides, occurring in a sequence encoding a non-structural protein (e.g., an alphavirus NSP4). [001064] In one example, the SG promoter is extended at the 5' end by approximately 12 nucleotides that occur in a sequence encoding a non-structural protein (e.g., an alphavirus NSP4). In another example, the extended SG promoter is encoded by a sequence established at SEQ ID NO: 13, extended at the 5' end by 12 nucleotides, present in a sequence encoding a non-structural protein (e.g., an alphavirus NSP4). For example, the extended SG promoter is no more than 61 nucleotides long. In another example, the extended SG promoter is encoded by a sequence comprising or consisting of nucleotides 41 to 101 of SEQ ID NO: 17. In another example, the extended SG promoter is encoded by a sequence comprising or consisting of a sequence established at SEQ ID NO: 14. [001065] In one example, the SG promoter is extended at the 5' end by approximately 31 nucleotides that occur in a sequence encoding a non-structural protein (e.g., an alphavirus NSP4). In another example, the extended SG promoter is encoded by a sequence established at SEQ ID NO: 13, extended at the end Petition 870260001818, dated 08 / 01 / 2026, page 138 / 357 134 / 291 5' by 31 nucleotides, present in a sequence that encodes a non-structural protein (e.g., an alphavirus NSP4). For example, the extended SG promoter is no more than 80 nucleotides long. In one example, the extended SG promoter is encoded by a sequence comprising or consisting of nucleotides 22 to 101 of SEQ ID NO: 17. In another example, the extended SG promoter is encoded by a sequence comprising or consisting of a sequence defined in SEQ ID NO: 15. [001066] In one example, the extended SG promoter comprises a repeated sequence corresponding to nucleotides 66 to 75 of SEQ ID NO: 17. For example, the extended SG promoter is encoded by a sequence comprising nucleotides 50 to 75 of SEQ ID NO: 17 and nucleotides 66 to 101 of SEQ ID NO: 17. For example, the extended SG promoter is encoded by a sequence established in SEQ ID NO: 27. [001067] In one example, the IRES is an IRES of encephalomyocarditis virus (EMCV), poliovirus (PV), human enterovirus, foot-and-mouth disease virus (FMDV), hepatitis C virus (HCV), classical swine fever virus (CSFV), murine leukemia virus (MLV), simian immunodeficiency virus (SIV), eukaryotic translation initiation factor 4G (elF4G), death-associated protein 5 (DAP5), cellular Myc (c-Myc), NF-κB repression factor (NRF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF-2), platelet-derived growth factor B (PDGF-B), Antennapedia, X-linked inhibitor of apoptosis (XIAP or Apaf-1), immunoglobulin heavy chain binding protein BiP or fibroblast growth factor 1a (FGF1A), GTX or a combination of both. [001068] In one example, the IRES is a wild-type IRES derived from encephalomyocarditis virus (EMCV). For example, the wild-type EMCV IRES comprises a sequence established in Petition 870260001818, dated 08 / 01 / 2026, page 139 / 357 135 / 291 SEQ ID NO: 16. [001069] In one example, the nucleotide sequence is optimized for codons. [001070] In one example, the G / C content of the nucleotide sequence is modified. [001071] In one example, the G / C content of the nucleotide sequence increases by at least 5% compared to the G / C content of the unmodified sequence. For example, the G / C content of the first and / or second nucleotide sequence and / or of one or more additional nucleotide sequences is increased by at least 10%, or 15%, or 20%, or 25%, or 30%, or 35%, or 40% compared to the G / C content of the unmodified sequence. [001072] In one example, the polynucleotide includes at least one chemically modified nucleotide. [001073] In one example, the chemically modified nucleotide is selected from the group consisting of N6,2'-O-dimethyladenosine (m6Am), 5-methyluridine (m5U), N4-acetylcytidine (ac4C), 2-thiocytidine (s2C), 2-thiouridine (s2U), 5-methylcytidine (m5C), N6-methyladenosine (m6a), pseudouridine (ψ), 1-methylpseudouridine (m1ψ), and combinations thereof. For example, the chemically modified nucleotide is N6,2'-O-dimethyladenosine (m6Am). For example, the chemically modified nucleotide is 5-methyluridine (m5U). For example, the chemically modified nucleotide is N4-acetylcytidine (ac4C). For example, the chemically modified nucleotide is 2-thiocytidine (s2C). For example, the chemically modified nucleotide is 2-thiouridine (s2U). For example, the chemically modified nucleotide is 5-methylcytidine (m5C). For example, the chemically modified nucleotide is N6-methyladenosine (m6a). For example, the chemically modified nucleotide is pseudouridine (ψ).For example, the chemically modified nucleotide is 1-methylpseudouridine (m1ψ). Petition 870260001818, dated 08 / 01 / 2026, page 140 / 357 136 / 291 [001074] In one example, the nucleotide sequence comprises the 5'-UTR region of haptoglobin (HP), fibrinogen beta chain (FGB), haptoglobin-related protein (HPR), albumin (ALB), complement component 3 (C3), fibrinogen alpha chain (FGA), collagen alpha 6 (Col6A), alpha-1-antitrypsin (SERPINA1), alpha-1-antichymotrypsin (SERPINA3), a fragment and / or a variant thereof. [001075] In one example, the 5'UTR is a 5'UTR of a Venezuelan equine encephalitis virus (VEEV) or its modified forms. For example, the 5'UTR comprises a sequence established in SEQ ID NO: 25. [001076] In one example, the 5'-UTR, its fragment and / or variant is between 40 and 2,000 nucleotides long. For example, the 5'-UTR, its fragment and / or its variant is between 40 and 100 nucleotides long. For example, the 5'-UTR, its fragment and / or its variant is between 100 and 250 nucleotides long. For example, the 5'-UTR, its fragment and / or its variant is between 250 and 500 nucleotides long. For example, the 5'-UTR, its fragment and / or its variant is between 500 and 750 nucleotides long. For example, the 5'-UTR, its fragment and / or its variant is between 750 and 1,000 nucleotides long. For example, the 5'UTR, its fragment and / or variant are between 1,000 and 1,250 nucleotides long. For example, the 5'-UTR, its fragment and / or variant are between 1,250 and 1,500 nucleotides long. For example, the 5'-UTR, its fragment and / or variant are between 1,500 and 1,750 nucleotides long.For example, the 5'-UTR, its fragment and / or variant, is between 1,750 and 2,000 nucleotides long. [001077] In one example, the 5'-UTR, the fragment and / or variant thereof comprises a nucleotide sequence with at least Petition 870260001818, dated 08 / 01 / 2026, page 141 / 357 137 / 291 90% identity with a nucleotide sequence established in any of the SEQ ID NO: 21 to 26. For example, the 5'-UTR, the fragment and / or the variant thereof comprise a nucleotide sequence 90%, or 91%, or 92%, or 93%, or 94%, or 95%, or 96%, or 97%, or 98%, or 99% identical to a nucleotide sequence established in any of the SEQ ID NO: 21 to 26. [001078] In one example, the polynucleotide comprises a combination of two or more 5'-UTRs, fragments and / or their variants. In one example, the two or more 5'-UTRs are the same. In one example, the two or more 5'-UTRs are different. [001079] In one example, the nucleotide sequence comprising the 5'UTR includes at least one microRNA binding site, an AU-rich element (ARE), a GC-rich element, a stem loop, and combinations thereof. In one example, the nucleotide sequence comprises a microRNA binding site. In one example, the nucleotide sequence comprises an AU-rich element (ARE). In one example, the nucleotide comprises a GC-rich element. In one example, the nucleotide sequence comprises a stem loop. For example, the stem loop is a histone stem loop. [001080] In one example, the polynucleotide further comprises a nucleotide sequence comprising a 3'UTR. In one example, the nucleotide sequence comprising the 3'UTR is located 3' from the second or one or more additional nucleotide sequences. For example, the nucleotide sequence comprising the 3'UTR is located 3' from the second nucleotide sequence. In one example, the 3'UTR comprises a 3'-UTR of arachidonate 5-lipoxygenase (ALOX5), collagen alpha I (COL1A1), tyrosine hydroxylase gene (TH), amino-terminal enhancer of cleavage (AES), human mitochondrial 12S rRNA (mtRNR1), a fragment and / or Petition 870260001818, dated 08 / 01 / 2026, page 142 / 357 138 / 291 a variant of these. [001081] In one example, the 3'UTR is a 3'UTR of a Sindbis virus (SINV) or its modified forms. For example, the 3'UTR comprises a sequence established in SEQ ID NO: 26. [001082] In one example, the 3'UTR, fragment and / or variant is between 40 and 400 nucleotides long. For example, the 3'-UTR is between 40 and 50, or 50 and 60, or 60 and 70, or 70 and 80, or 80 and 90, or 90 and 100, or 100 and 125, or 125 and 150, or 150 and 175, or 175 and 200, or 200 and 225, or 225 and 250, or 250 and 275, or 275 and 300, or 300 and 325, or 325 and 350, or 350 and 375, or 375 and 400 nucleotides in length. For example, the 3'-UTR, the fragment and / or its variant are between 40 and 50 nucleotides in length. For example, the 3'-UTR, the fragment and / or its variant are between 50 and 60 nucleotides long. For example, the 3'-UTR, the fragment and / or its variant are between 60 and 70 nucleotides long. For example, the 3'-UTR, the fragment and / or its variant are between 70 and 80 nucleotides long. For example, the 3'-UTR, the fragment and / or its variant are between 80 and 90 nucleotides long.For example, the 3'UTR, the fragment, and / or its variant are between 90 and 100 nucleotides long. For example, the 3'-UTR, the fragment, and / or its variant are between 100 and 125 nucleotides long. For example, the 3'-UTR, the fragment, and / or its variant are between 125 and 150 nucleotides long. For example, the 3'-UTR, the fragment, and / or its variant are between 150 and 175 nucleotides long. For example, the 3'-UTR, the fragment, and / or its variant are between 175 and 200 nucleotides long. For example, the 3'-UTR, the fragment, and / or its variant are between 200 and 225 nucleotides long. For example, the 3'-UTR, the fragment and / or its variant are between 225 and 250 nucleotides long. For example, the 3'-UTR, the fragment and / or its variant are between 250 and 275 nucleotides long. Petition 870260001818, dated 08 / 01 / 2026, page 143 / 357 139 / 291 nucleotides in length. For example, the 3'-UTR, the fragment and / or its variant are between 275 and 300 nucleotides in length. For example, the 3'-UTR, the fragment and / or its variant are between 300 and 325 nucleotides in length. For example, the 3'-UTR, the fragment and / or its variant are between 325 and 350 nucleotides in length. For example, the 3'-UTR, the fragment and / or its variant are between 350 and 375 nucleotides in length. For example, the 3'-UTR, the fragment and / or its variant are between 375 and 400 nucleotides in length. [001083] In one example, the polynucleotide comprises a combination of two or more 3'-UTRs, fragments and / or their variants. In one example, the two or more 3'-UTRs are the same. In one example, the two or more 3'-UTRs are different. [001084] In one example, the nucleotide sequence comprising the 3'UTR, the fragment and / or its variant comprises at least one microRNA binding site, an AU-rich element (ARE), a GC-rich element, a triple helix, a stem loop, one or more stop codons, and combinations thereof. In one example, the nucleotide sequence comprises a microRNA binding site. In one example, the nucleotide sequence comprises an AU-rich element (ARE). In one example, the nucleotide sequence comprises a GC-rich element. In one example, the nucleotide sequence comprises a triple helix. In one example, the nucleotide sequence comprises a stem loop. For example, the stem loop is a histone stem loop. In one example, the nucleotide sequence comprises one or more stop codons. For example, one or more stop codons are located at the 5' end of the 3'-UTR. [001085] In one example, the polynucleotide comprises a sequence of nucleotides comprising one or more sequences of Petition 870260001818, dated 08 / 01 / 2026, page 144 / 357 140 / 291 3' tails located at the 3' end of the nucleotide sequence comprising the 3'UTR. In one example, one or more 3' tail sequences are selected from the group consisting of a poly-A sequence, a polyadenylation signal, a G-quadruplex, a poly-C sequence, a stem loop, and combinations thereof. For example, the 3' tail sequence comprises a poly-A sequence. In one example, the 3' tail sequence comprises a polyadenylation signal. In one example, the 3' tail sequence comprises a G-quadruplex. In one example, the 3' tail sequence comprises a poly-C sequence. In one example, the 3' tail sequence comprises a stem loop. For example, the stem loop is a histone stem loop. In one example, the 3' tail sequence comprises a poly-A sequence and a G-quadruplex. In one example, the 3' tail sequence comprises a stem loop (e.g., a histone stem loop) and a poly-A sequence. [001086] In one example, one or more 3' tail sequences comprise one or more poly-A sequences, each comprising between 10 and 300 consecutive adenosine nucleotides. For example, each of the poly-A sequences comprises between 10 and 20, or 20 and 30, or 30 and 40, or 40 and 50, or 50 and 60, or 60 and 70, or 70 and 80, or 80 and 90, or 90 and 100, or 100 and 125, or 125 and 150, or 150 and 175, or 175 and 200, or 200 and 225, or 225 and 250, or 250 and 275, or 275 and 300 consecutive adenosine nucleotides. For example, one or more poly-A sequences comprise between 10 and 20 consecutive adenosine nucleotides. For example, one or more poly-A sequences comprise between 20 and 30 consecutive adenosine nucleotides. For example, one or more poly-A sequences comprise between 30 and 40 consecutive adenosine nucleotides. For example, one or more poly-A sequences each comprise 36 consecutive adenosine nucleotides. For example, one or more poly-A sequences Petition 870260001818, dated 01 / 08 / 2026, pp. 145 / 357 141 / 291 comprise between 40 and 50 consecutive adenosine nucleotides. For example, one or more poly-A sequences comprise between 50 and 60 consecutive adenosine nucleotides. For example, one or more poly-A sequences comprise between 60 and 70 consecutive adenosine nucleotides. For example, one or more poly-A sequences comprise between 70 and 80 consecutive adenosine nucleotides. For example, one or more poly-A sequences comprise between 80 and 90 consecutive adenosine nucleotides. For example, one or more poly-A sequences comprise between 90 and 100 consecutive adenosine nucleotides. For example, one or more poly-A sequences comprise between 100 and 125 consecutive adenosine nucleotides. For example, one or more poly-A sequences comprise between 125 and 150 consecutive adenosine nucleotides. For example, one or more poly-A sequences comprise between 150 and 175 consecutive adenosine nucleotides.For example, one or more poly-A sequences comprise between 175 and 200 consecutive adenosine nucleotides. For example, one or more poly-A sequences comprise between 200 and 225 consecutive adenosine nucleotides. For example, one or more poly-A sequences comprise between 225 and 250 consecutive adenosine nucleotides. For example, one or more poly-A sequences comprise between 250 and 275 consecutive adenosine nucleotides. For example, one or more poly-A sequences comprise between 275 and 300 consecutive adenosine nucleotides. [001087] In one example, each of the poly-A sequences comprises 10, or 20, or 30, or 40, or 50, or 60, or 70, or 80, or 90, or 100, or 125, or 150, or 175, or 200, or 225, or 250, or 275, or 300 consecutive adenosine nucleotides. For example, the sequence of one or more poly-A sequences comprises 10 consecutive adenosine nucleotides. For example, the sequence of one or more poly-A sequences comprises Petition 870260001818, dated 01 / 08 / 2026, pp. 146 / 357 142 / 291 consecutive adenosine nucleotides. For example, the sequence of one or more poly-A groups comprises 30 consecutive adenosine nucleotides. For example, the sequence of one or more poly-A groups comprises 40 consecutive adenosine nucleotides. For example, the sequence of one or more poly-A groups comprises 50 consecutive adenosine nucleotides. For example, the sequence of one or more poly-A groups comprises 60 consecutive adenosine nucleotides. For example, the sequence of one or more poly-A groups comprises 70 consecutive adenosine nucleotides. For example, the sequence of one or more poly-A groups comprises 80 consecutive adenosine nucleotides. For example, the sequence of one or more poly-A groups comprises 90 consecutive adenosine nucleotides. For example, the sequence of one or more poly-A groups comprises 100 consecutive adenosine nucleotides. For example, the sequence of one or more poly-A groups comprises 125 consecutive adenosine nucleotides.For example, the sequence of one or more poly-A groups comprises 150 consecutive adenosine nucleotides. For example, the sequence of one or more poly-A groups comprises 175 consecutive adenosine nucleotides. For example, the sequence of one or more poly-A groups comprises 200 consecutive adenosine nucleotides. For example, the sequence of one or more poly-A groups comprises 225 consecutive adenosine nucleotides. For example, the sequence of one or more poly-A groups comprises 250 consecutive adenosine nucleotides. For example, the sequence of one or more poly-A groups comprises 275 consecutive adenosine nucleotides. For example, the sequence of one or more poly-A groups comprises 300 consecutive adenosine nucleotides. [001088] In one example, the poly-A sequence comprises 36 consecutive adenosine nucleotides. For example, the polyA sequence comprises a sequence established in SEQ ID NO: 28. [001089] In one example, one or more poly-A sequences are Petition 870260001818, dated 08 / 01 / 2026, pp. 147 / 357 143 / 291 separated by a stop linker. For example, the 3' tail sequence comprises, in the order from 5' to 3': a poly-A sequence comprising consecutive adenosine nucleotides, a stop linker, and an additional poly-A sequence comprising consecutive adenosine nucleotides. [001090] In one example, the stop linker is 10 to 50, or 50 to 100, or 100 to 150 nucleotides long. For example, the stop linker is 10 to 50 nucleotides long. For example, the stop linker is 50 to 100 nucleotides long. For example, the stop linker is 100 to 150 nucleotides long. [001091] In one example, the break linker is 1, or 2, or 3, or 4, or 5, or 6, or 7, or 8, or 9, or 10, or 11, or 12, or 13, or 14, or 15, or 16, or 17, or 18, or 19, or 20, or 25, or 30, or 35, or 40, or 45, or 50, or 55, or 60, or 65, or 70, or 75, or 80, or 85, or 90, or 95, or 100, or 110, or 120, or 130, or 140, or 150 nucleotides in length. For example, the stop linker is 1 nucleotide long. For example, the stop linker is 2 nucleotides long. For example, the stop linker is 3 nucleotides long. For example, the stop linker is 4 nucleotides long. For example, the stop linker is 5 nucleotides long. For example, the stop linker is 6 nucleotides long. For example, the stop linker is 7 nucleotides long. For example, the stop linker is 8 nucleotides long. For example, the stop linker is 9 nucleotides long. For example, the stop linker is 10 nucleotides long. For example, the stop ligand is 11 nucleotides long. For example, the stop ligand is 12 nucleotides long.For example, the stop ligand has 13 nucleotides. Petition 870260001818, dated 08 / 01 / 2026, pp. 148 / 357 144 / 291 in length. For example, the stop linker is 14 nucleotides long. For example, the stop linker is 15 nucleotides long. For example, the stop linker is 16 nucleotides long. For example, the stop linker is 17 nucleotides long. For example, the stop linker is 18 nucleotides long. For example, the stop linker is 19 nucleotides long. For example, the stop linker is 20 nucleotides long. For example, the stop linker is 25 nucleotides long. For example, the stop linker is 30 nucleotides long. For example, the stop linker is 35 nucleotides long. For example, the stop linker is 40 nucleotides long. For example, the stop ligand is 45 nucleotides long. For example, the stop ligand is 50 nucleotides long.For example, the stop ligand is 55 nucleotides long. For example, the stop ligand is 60 nucleotides long. For example, the stop ligand is 65 nucleotides long. For example, the stop ligand is 70 nucleotides long. For example, the stop ligand is 75 nucleotides long. For example, the stop ligand is 80 nucleotides long. For example, the stop ligand is 85 nucleotides long. For example, the stop ligand is 90 nucleotides long. For example, the stop ligand is 95 nucleotides long. For example, the stop ligand is 100 nucleotides long. For example, the stop ligand is 110 nucleotides long. For example, the stop ligand is 120 nucleotides long. For example, the stopping ligand is 130 nucleotides long.For example, the stopping ligand has 140 nucleotides. Petition 870260001818, dated 08 / 01 / 2026, page 149 / 357 145 / 291 nucleotides in length. For example, the stopping ligand is 150 nucleotides long. [001092] In one example, the stop linker is 10 nucleotides long. In one example, the stop linker comprises or consists of the nucleotide sequence set forth in SEQ ID NO: 20. For example, the stop linker comprises or consists of a nucleotide sequence GCAUAUGACU. [001093] In one example, the 3' tail sequence comprises, in the order of 5' to 3': a poly-A sequence comprising 30 consecutive adenosine nucleotides, a 10-nucleotide break linker, and an additional poly-A sequence comprising 70 consecutive adenosine nucleotides. [001094] In one example, the 3' tail sequence comprises, in the order of 5' to 3': a poly-A sequence comprising 30 consecutive adenosine nucleotides, a break linker comprising or consisting of the nucleotide sequence set forth in SEQ ID NO: 20, and an additional poly-A sequence comprising 70 consecutive adenosine nucleotides. [001095] In one example, RNA also comprises a 5' terminal cap structure. [001096] In one example, the 5' terminal cap structure is an endogenous cap or an analogue thereof. For example, the 5' terminal cap structure is an endogenous cap. For example, the 5' terminal cap structure is an analogue of an endogenous cap. [001097] In one example, the 5'-terminal cap structure comprises a guanine or a guanine analogue. For example, the 5'-terminal cap structure comprises a guanine. For example, the 5'-terminal cap structure comprises a guanine analogue of a guanine. [001098] In one example, the 5' terminal cap structure is selected from a group consisting of an antireverse cap analog (ARCA), Petition 870260001818, dated 08 / 01 / 2026, page 150 / 357 146 / 291 N7,2'-0-dimethyl-guanosine (mCAP), inosine, Nl-methyl-guanosine, 2'-fluoroguanosine, 7-deazaguanosine, 8-oxoguanosine, 2-aminoguanosine, LNA-guanosine, 2-azidoguanosine, N6,2'-O-dimethyladenosine, 7-methylguanosine (m7G), Cap1 and Cap2. For example, the 5'-terminal cap structure is analogous to the antireversal cap (ARCA). For example, the 5'-terminal cap structure is N7,2'-O-dimethylguanosine (mCAP). For example, the 5'-terminal cap structure is inosine. For example, the 5'-terminal cap structure is N1-methylguanosine. For example, the 5'-terminal cap structure is 2'-fluoroguanosine. For example, the 5'-terminal cap structure is 7-deazaguanosine. For example, the 5'-terminal cap structure is 8-oxoguanosine. For example, the 5'-terminal cap structure is 2-aminoguanosine. For example, the 5'-terminal cap structure is LNAguanosine. For example, the 5'-terminal cap structure is 2-azidoguanosine. For example, the 5'-terminal structure is N6,2'-O-dimethyladenosine. For example, the 5'-terminal cap structure is 7-methylguanosine (m7G).For example, the 5' terminal cap structure is Cap1. For example, the 5' terminal cap structure is Cap2. [001099] In one example, the 5'-terminal cap structure is linked to the 5' end of the RNA by a 5'-5'-triphosphate bond or a 5'-5'-phosphorothioate bond. For example, the 5'-terminal cap structure is linked to the 5' end of the RNA by a 5'-5'-triphosphate bond. For example, the 5'-terminal cap structure is linked to the 5' end of the RNA by a 5'-5'-phosphorothioate bond. [001100] In one example, the self-replicating RNA is from an alphavirus. For example, the alphavirus is selected from the group consisting of Semliki Forest virus (SFV), Sindbis virus (SIN), and Venezuelan equine encephalitis virus (VEE), as well as combinations thereof. [001101] In one example, the self-replicating RNA is from a Semliki Forest virus (SFV). Petition 870260001818, dated 08 / 01 / 2026, pp. 151 / 357 147 / 291 [001102] In one example, the self-replicating RNA comes from a Sindbis (SIN) virus. [001103] In one example, the self-replicating RNA comes from a Venezuelan equine encephalitis (VEE) virus. [001104] In one example, self-replicating RNA comprises or consists of a polynucleotide sequence according to SEQ ID NO: 30. [001105] In one example, the antigen is selected from the group consisting of a respiratory syncytial virus (RSV), an influenza virus, and / or a SARS-CoV-2. [001106] In one example, the antigen is from a respiratory syncytial virus (RSV). [001107] In one example, the antigen is from influenza. [001108] In one example, the antigen is from SARS-CoV-2. [001109] In one example, the antigens are from a single strain of an influenza virus (i.e., monovalent) or from multiple strains (i.e., multivalent). For example, the immunogenic composition includes antigens from one or more (e.g., 1, 2, or 3) strains of the influenza virus. [001110] In one example, the composition comprises first- and second-generation influenza viral antigens from different strains of the influenza virus. In another example, the composition comprises first-, second-, and third-order influenza viral antigens from different strains of the influenza virus. For example, the composition comprises (i) an RNA comprising a nucleotide sequence encoding a first influenza antigen; and (ii) a polypeptide antigen from a different influenza strain. In another example, the composition comprises (i) an RNA comprising a nucleotide sequence encoding a first influenza antigen; (ii) an RNA comprising a nucleotide sequence encoding a first influenza antigen; Petition 870260001818, dated 08 / 01 / 2026, page 152 / 357 148 / 291 encodes a second influenza antigen and (iii) a polypeptide of a third influenza antigen. In another example, the composition comprises (i) an RNA comprising a nucleotide sequence encoding a first influenza antigen of influenza A virus; (ii) an RNA comprising a nucleotide sequence encoding a second influenza antigen of influenza B virus and (iii) a polypeptide of a third influenza antigen of influenza C virus. [001111] In one example, the antigens are from a strain of influenza A virus. For example, the antigens are a hemagglutinin (HA) protein from influenza A virus, a neuraminidase (NA) protein, a matrix protein (M), a nucleoprotein (NP), a non-structural protein (NS), or an immunogenic fragment or variant thereof. In one example, the antigens are a hemagglutinin (HA) subtype of influenza A H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, or H16 and / or a neuraminidase (NA) subtype of influenza A N1, N2, N3, N4, N5, N6, N7, N8, or N9 and / or a matrix protein (M) subtype of influenza A M1 or M2 and / or a non-structural protein (NS) subtype of influenza A NS1 or NS2. [001112] In one example, influenza viral antigens are from different subtypes of the influenza virus. For example, different hemagglutinin subtypes and / or different neuraminidase subtypes and / or matrix protein subtypes and / or nucleoprotein subtypes and / or non-structural protein subtypes. [001113] A person skilled in the art will know that pandemic strains of influenza virus are generally strains of influenza A virus of subtypes H1, H2, H3, H5, H6, H7, or H9. For example, strains H1N1, H2N2, H3N2, H5N1, H5N3, H6N1, H7N2, H7N3, H7N7, H7N9, and H9N2. In one example, the antigen is an H1N1 antigen of a viral strain A / Delaware / 55 / 2019. In another example, the antigen is an H1 antigen of a viral strain A / Delaware / 55 / 2019. Petition 870260001818, dated 08 / 01 / 2026, pp. 153 / 357 149 / 291 [001114] In one example, the antigens are from influenza A virus strains that have the same hemagglutinin subtypes. In another example, the antigens are influenza A virus strains that have different hemagglutinin subtypes. In one example, the antigens are influenza A virus strains of subtypes H1, H2, H3, H5, H6, H7, or H9. For example, the antigens are an H1 hemagglutinin, or an H2 hemagglutinin, or an H3 hemagglutinin, or an H5 hemagglutinin, or an H6 hemagglutinin, or an H7 hemagglutinin, or an H9 hemagglutinin. For example, the antigens are an influenza A virus strain of subtype H5 (i.e., an H5 hemagglutinin). In one example, the H5 hemagglutinin is a viral strain A / turkey / Turkey / 1 / 2005. In one example, hemagglutinin H3 is a viral strain A / Delaware / 39 / 2019. [001115] In one example, the antigens are strains of influenza A virus that have the same neuraminidase subtypes. In another example, the antigens are strains of influenza A virus that have different neuraminidase subtypes. In one example, the antigens are strains of influenza A virus of subtypes N1, N2, N3, N7, or N9. For example, the antigens are a neuraminidase N1, or a neuraminidase N2, or a neuraminidase N3, or a neuraminidase N7, or a neuraminidase N9. For example, the antigens are a strain of influenza A virus of neuraminidase subtype N1. In one example, neuraminidase N1 is a strain A / turkey / Turkey / 1 / 2005. In one example, neuraminidase N2 is a strain of the virus A / Delaware / 39 / 2019. [001116] In one example, the antigens are a hemagglutinin H5 protein and / or a neuraminidase N1 protein. For example, the first antigen is a strain of influenza A virus of the hemagglutinin H5 subtype and the second antigen is a strain of influenza A virus of the neuraminidase N1 subtype. Petition 870260001818, dated 08 / 01 / 2026, pp. 154 / 357 150 / 291 [001117] In one example, the antigens are a strain of influenza B virus. A qualified professional will know that influenza B viruses are not divided into subtypes, but classified into two lineages, namely B / Yamagata and B / Victoria. [001118] In one example, the antigens are a strain of influenza B / Yamagata virus. For example, the influenza B virus strain is a strain of B / Singapore / INFTT 16 0610 / 16 (By). In another example, the antigens are a strain of influenza B / Victoria virus. In one example, the antigens are strains of influenza B virus from the same lineage. In another example, the antigens are strains of influenza B virus from different lineages. [001119] In one example, the antigens are a Hyam protein from the influenza B virus and / or a Nyam protein. For example, the antigens are a Hyam protein from the influenza B virus. In another example, the antigens are a Nyam protein from the influenza B virus. In yet another example, the antigens are both the Hyam and Nyam proteins from the influenza B virus. [001120] In one example, the antigen is an H1N1 influenza A antigen and is encoded by a sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to SEQ ID NO: 5. In another example, the antigen is an H5N1 influenza A antigen and is encoded by a sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or 100% identical to SEQ ID NO: 7. Petition 870260001818, dated 01 / 08 / 2026, pp. 155 / 357 151 / 291 [001121] In one example, the antigen is an H1N1 influenza A antigen and has an amino acid sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to SEQ ID NO: 6. In another example, the antigen is an H5N1 influenza A antigen and has an amino acid sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or 100% identical to SEQ ID NO: 8. [001122] In one example, the antigen is from influenza B. [001123] In one example, the antigen is for influenza C. [001124] In one example, the antigens are from a single strain of SARS-CoV-2 (i.e., monovalent) or from multiple strains of SARS-CoV-2 (i.e., multivalent). For example, the immunogenic composition includes antigens from one or more (e.g., 1, 2, or 3) strains of SARS-CoV-2. [001125] In one example, the composition comprises primary and secondary SARS-CoV-2 antigens from different strains of SARS-CoV-2. In another example, the composition comprises the first, second, and third SARS-CoV-2 antigens from different strains of the SARS-CoV-2 virus. For example, the composition comprises (i) an RNA comprising a nucleotide sequence encoding a primary SARS-CoV-2 antigen; and (ii) a polypeptide antigen from a different strain of SARS-CoV-2. In another example, the composition comprises (i) an RNA comprising a nucleotide sequence encoding a primary SARS-CoV-2 antigen; (ii) a Petition 870260001818, dated 08 / 01 / 2026, pp. 156 / 357 152 / 291 RNA comprising a nucleotide sequence encoding a second SARS-CoV-2 antigen and (iii) a polypeptide of a third SARS-CoV-2 antigen. In another example, the composition comprises (i) an RNA comprising a nucleotide sequence encoding a first SARS-CoV-2 antigen from a delta strain of SARS-CoV-2; (ii) an RNA comprising a nucleotide sequence encoding a second SARS-CoV-2 antigen from an Omicron strain of SARS-CoV-2 and (iii) a polypeptide of a third SARS-CoV-2 antigen from a Wuhan (original) strain of SARS-CoV-2. In another example, the antigens are from one or more of the following strains of SARS-CoV-2: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P1), Epsilon (B.1.429), Delta mutant (B.1.617.2), Kappa mutant (B.1.617.1), Wuhan (original) strain, and / or Omicron strain (B.1.1.529). [001126] In one example, the antigens are a spike (S) protein and / or a nucleocapsid (N) protein of SARS-CoV-2. For example, the antigens are an N protein and / or an S protein of SARS-CoV-2 from the Alpha strain (B.1.1.7), the Beta strain (B.1.351), the Gamma strain (P1), the Epsilon strain (B.1.429), the Delta mutant (B.1.617.2), the Kappa mutant (B.1.617.1), the Wuhan (original) strain, and / or the Omicron strain (B.1.1.529). In one example, the antigens are an N protein of SARS-CoV-2 and / or an S protein of the original (Wuhan) strain of SARS-CoV-2. In one example, the antigens are an N protein of SARS-CoV-2 and / or an S protein of the delta strain of SARS-CoV-2. In one example, the antigens are an N protein from SARS-CoV-2 and / or an S protein from the Omicron delta strain of SARS-CoV-2. [001127] In one example, the antigen is an N protein of SARS-CoV-2. [001128] In another example, the antigen is an ectodomain of the S protein of the Omicron strain of SARS-CoV-2. [001129] For example, the antigen is an ectodomain of the S protein. Petition 870260001818, dated 01 / 08 / 2026, pp. 157 / 357 153 / 291 of SARS-CoV-2 encoded by a sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the sequence as set out in SEQ ID NO: 9 or 11. [001130] In another example, the antigen is an ectodomain of the S protein of the SARS-CoV-2 spike protein that has a sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the sequence as established in SEQ ID NO: 10 or 12. [001131] In another example, the S protein is a mutant S protein. [001132] In one example, a mutant S protein includes a mutation in the receptor-binding domain. For example, the mutation is selected from the group consisting of S438F, N439K, N440K, L441I, K444R, V445A, V445I, G446V, G446S, N450K, L452R, L452P, L455F, K458N, N460T, D467V, I468F, I468T, I468V, E471O, I472V, A475V, G476S, S477G, S477I, S477N, S477R, T478I, P479L, P479L, P479S, N481D, N481H, V483F, V483A, E484D, E484K, E484K, E484O, G485S, Y489H, Y489D, Y489F, Y489C, Y489N, F490L, F490S, P491R, Q493L, S494P, Y495N, T500N, N501S, and Y505H, Y508H. In one example, a mutant S protein includes a mutation in the receptor-binding domain selected from the group consisting of N439K, N439L, L452R, S477N, T478I, V483A, and E484D. [001133] In one example, a mutant S protein includes a mutation in the receptor-binding domain. For example, the mutation is selected from the group consisting of R346K, K417N, K417T, S438F, Petition 870260001818, dated 01 / 08 / 2026, pp. 158 / 357 154 / 291 N439K, N440K, L441I, K444R, V445A, V445I, G446V, G446S, N450K, L452R, L452P, L455F, K458N, N460T, D467V, I468F, I468T, I468V, E471O, I472V, A475V, G476S, S477G, S477I, S477N, S477R, T478I, T478K, P479L, P479S, N481D, N481H, V483F, V483A, E484D, E484K, E484K, E484O, G485S, Y489H, Y489D, Y489F, Y489C, Y489N, F490L, F490S, P491R, Q493L, S494P, Y495N, T500N, N501S, N501Y, Y505H, and Y508H. In one example, a mutant S protein includes a mutation in the receptor-binding domain selected from the group consisting of R346K, K417N, K417T, N439K, N439L, L452R, S477N, T478I, V483A, E484D, E484K, and N501Y. [001134] In one example, a mutant S protein comprises a mutation selected from the group consisting of P337S, F338L, F338C, G339D, E340K, V341I, A344S, T345S, R346K, A348S, A348T, W353R, N354D, N354K, N354S, S359N, D364Y, V367F, S373L, V382L, P384L, P384S, T385A, T393P, V395I, F400C, R403K, R403S, D405V, R408I, Q414E, Q414K, Q414P, Q414R, T415S, K417R, K417N, I418V, Y421S, Y423C, Y423F, Y423S, D427Y, R509K, V510L, V511E, V512L, L518I, H519O, A520S, A520V, P521R, P521S, A522P, and D614G. [001135] In one example, a mutant S protein comprises a selected mutation from the group consisting of L18F, D80A, T95I, Y144S, Y145N, D215G, P337S, F338L, F338C, G339D, E340K, V341I, A344S, T345S, R346K, A348S, A348T, W353R, N354D, N354K, N354S, S359N, D364Y, V367F, S373L, V382L, P384L, P384S, T385A, T393P, V395I, F400C, R403K, R403S, D405V, R408I, Q414E, Q414K, Q414P, Q414R, T415S, K417N, K417T, K417R, I418V, Y421S, Y423C, Y423F, Y423S, D427Y, S438F, N439K, N440K, L441I, K444R, V445A, V445I, G446V, G446S, N450K, L452R, L452P, L455F, K458N, N460T, D467V, I468F, I468T, I468V, E471O, I472V, A475V, G476S, S477G, S477I, S477N, S477R, T478I, T478K, P479L, P479S, N481D, Petition 870260001818, dated 08 / 01 / 2026, pp. 159 / 357 155 / 291 N481H, V483F, V483A, E484D, E484K, E484K, E484O, G485S, Y489H, Y489D, Y489F, Y489C, Y489N, F490L, F490S, P491R, Q493L, S494P, Y495N, T500N, N501S, N501Y, Y505H, Y508H, R509K, V510L, V511E, V512L, L518I, H519O, A520S, A520V, P521R, P521S, A522P, A522S, A570D, D614G, P680H, P681H, A701V, T716I and D950N. [001136] In one example, the S protein does not have a furin cleavage site at the S1 / S2 boundary and / or at the S2' site. [001137] In one example, the mutant S protein comprises mutations (e.g., substitutions) that stabilize the S protein in a pre-fusion conformation. For example, the S protein exhibits the K986P and V987P substitutions. [001138] In one example, the antigens are from a single strain of a respiratory syncytial virus (RSV) (i.e., monovalent) or from multiple strains (i.e., multivalent) of an RSV. For example, the immunogenic composition includes antigens from one or more (e.g., 1, 2, or 3) strains of RSV (Respiratory Syncytial Virus). [001139] In one example, the composition comprises primary and secondary RSV antigens from different RSV strains. In another example, the composition comprises the first, second, and third RSV (Respiratory Syncytial Virus) antigens from different strains of the virus. For example, the composition comprises (i) an RNA comprising a nucleotide sequence encoding a first RSV antigen; and (ii) a polypeptide antigen from a different RSV strain. In another example, the composition comprises (i) an RNA comprising a nucleotide sequence encoding a first RSV antigen; (ii) an RNA comprising a nucleotide sequence encoding a second RSV antigen; and (iii) a polypeptide of a third RSV antigen. [001140] For example, the antigen is selected from a gli Petition 870260001818, dated 08 / 01 / 2026, page 160 / 357 156 / 291 RSV surface copolymer, including a fusion protein (F), glycoprotein (G), small hydrophobic protein (SH), matrix proteins M and M2, nucleocapsid proteins N, P, and L, and non-structural proteins NS1 and NS2. In certain examples, the first and second antigens are both RSV-F antigens. In certain examples, the first, second, and third antigens are each an RSV-F antigen. [001141] In one example, the antigen is a Pre F protein of an RSV encoded by a sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to SEQ ID NO: 1 or 3. [001142] In one example, the antigen is a Pre F protein from an RSV that has a sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to SEQ ID NO: 2 or 4. [001143] In one example, the antigen comes from a G protein of an RSV. [001144] In one example, the composition further comprises one or more additional antigens. In some examples, the composition will therefore include a third antigen. In another example, the composition will include a fourth antigen. In one example, one or more additional antigens, or a third or fourth antigen, are viral antigens. For example, the viral antigen is from a respiratory virus. In one example, the respiratory virus is selected from the group consisting of Petition 870260001818, dated 08 / 01 / 2026, page 161 / 357 157 / 291 influenza virus, respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, coronavirus, adenovirus and bocavirus. [001145] In one example, one or more additional viral antigens are derived from an influenza virus. [001146] In one example, the one or more additional viral antigens are from a respiratory syncytial virus. [001147] In one example, the one or more additional viral antigens are from a parainfluenza virus. [001148] In one example, the one or more additional viral antigens are from a metapneumovirus. [001149] In one example, the one or more additional viral antigens are from a rhinovirus. [001150] In one example, the one or more additional viral antigens are from a coronavirus. [001151] In one example, the one or more additional viral antigens are from an adenovirus. [001152] In one example, the one or more additional viral antigens are from a bocavirus. [001153] In one example, the one or more additional antigens are viral antigens from an influenza virus or a coronavirus. [001154] In one example, the first, second, third, and / or fourth antigens are expressed at substantially equal levels. For example, the antigens exhibit expression levels that differ from each other by about 10%, 5%, or 1%. In another example, the first, second, third, and / or fourth antigens are expressed at different levels. For example, the antigens exhibit expression levels that are about 10%, or about 15%, or about 20% higher than each other. The methods for determining the expression level are known in the art and / or are described in this document. [001155] This publication also offers a composition Petition 870260001818, dated 08 / 01 / 2026, page 162 / 357 158 / 291 pharmaceutical comprising an immunogenic composition of the present disclosure and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers suitable for use in the present disclosure will be apparent to a person skilled in the art and / or are described herein. [001156] In one example, the pharmaceutical composition further comprises a lipid nanoparticle (LNP), a polymeric microparticle, and an oil-in-water emulsion. For example, the polynucleotide, RNA, cRNA, or self-replicating RNA is encapsulated, bound, or adsorbed onto an LNP, a polymeric microparticle, and an oil-in-water emulsion. In one example, the polynucleotide is encapsulated, bound, or adsorbed onto an LNP, a polymeric microparticle, and an oil-in-water emulsion. In another example, the RNA is encapsulated, bound, or adsorbed onto an LNP, a polymeric microparticle, and an oil-in-water emulsion. For example, the cRNA is encapsulated, bound, or adsorbed onto an LNP, a polymeric microparticle, and an oil-in-water emulsion. For example, self-replicating RNA is encapsulated, bound, or adsorbed onto an LNP, a polymeric microparticle, and an oil-in-water emulsion. [001157] In one example, the pharmaceutical composition further comprises an LNP. For example, the polynucleotide is encapsulated in an LNP. In another example, RNA is encapsulated in an LNP. For example, cRNA is encapsulated in an LNP. For example, self-replicating RNA is encapsulated in an LNP. For example, the polynucleotide is linked to an LNP. In another example, RNA is linked to an LNP. For example, cRNA is linked to an LNP. In another example, self-replicating RNA is linked to an LNP. For example, the polynucleotide is adsorbed onto an LNP. In another example, RNA is adsorbed onto an LNP. For example, cRNA is adsorbed onto an LNP. In yet another example, self-replicating RNA is adsorbed onto an LNP. Petition 870260001818, dated 08 / 01 / 2026, page 163 / 357 159 / 291 an LNP. In another example, each RNA is formulated together in the LNP. In another example, each RNA is formulated separately in the LNP. [001158] In one example, where multiple RNAs are considered, the RNAs are contained within the same LNP. In another example, the multiple RNAs are contained in different LNPs. [001159] In one example, the composition also includes an additional RNA that codes for: [001160] (i) one or more antigens; [001161] (ii) one or more immunopotentiating agents; [001162] (iii) one or more chemoattractants; and / or [001163] (iv) one or more targeting molecules. [001164] In one example, the additional RNA is contained in the same LNP as the RNA that encodes the antigen, or it is contained in a separate LNP from the RNA that encodes the antigen. [001165] In one example, the LNP comprises a PEG lipid, a structural lipid, and / or a neutral lipid. For example, the LNP comprises a PEG lipid, a structural lipid, and a neutral lipid. In another example, the LNP comprises a PEG lipid, a structural lipid, or a neutral lipid. [001166] In one example, the LNP also comprises a cationic lipid. In another example, the LNP does not comprise a cationic lipid. [001167] In one example, the pharmaceutical composition further comprises a polymeric microparticle. For example, the polynucleotide is encapsulated in a polymeric microparticle. In another example, RNA is encapsulated in a polymeric microparticle. For example, cRNA is encapsulated in a polymeric microparticle. For example, self-replicating RNA is encapsulated in a polymeric microparticle. For example, the polynucleotide is linked to a polymeric microparticle. In another example, RNA is linked to a microparticle Petition 870260001818, dated 08 / 01 / 2026, page 164 / 357 160 / 291 polymeric. For example, cRNA is attached to a polymeric microparticle. In another example, self-replicating RNA is attached to a polymeric microparticle. For example, the polynucleotide is adsorbed onto a polymeric microparticle. In another example, RNA is adsorbed onto a polymeric microparticle. For example, cRNA is adsorbed onto a polymeric microparticle. In yet another example, self-replicating RNA is adsorbed onto a polymeric microparticle. [001168] In one example, the pharmaceutical composition further comprises an oil-in-water emulsion. For example, the polynucleotide is encapsulated in an oil-in-water emulsion. In another example, RNA is encapsulated in an oil-in-water emulsion. For example, cRNA is encapsulated in an oil-in-water emulsion. For example, self-replicating RNA is encapsulated in an oil-in-water emulsion. For example, the polynucleotide is bound to an oil-in-water emulsion. In another example, RNA is bound to an oil-in-water emulsion. For example, cRNA is bound to an oil-in-water emulsion. In another example, self-replicating RNA is bound to an oil-in-water emulsion. In another example, self-replicating RNA is adsorbed onto an oil-in-water emulsion. In another example, self-replicating RNA is resuspended in an oil-in-water emulsion. [001169] The present disclosure also offers an immunogenic composition or a pharmaceutical composition of the disclosure for use as a vaccine. [001170] In one example, the polynucleotide is DNA. In one example, the DNA encodes a cRNA described in this document. In one example, the DNA encodes a self-replicating RNA vaccine described in this document. [001171] In one example, DNA is a plasmid. [001172] This disclosure offers a method for treating, pre Petition 870260001818, dated 08 / 01 / 2026, page 165 / 357 161 / 291 to stop or delay the progression of a disease or condition in a subject, the method comprising administering the immunogenic composition or pharmaceutical composition of this disclosure to a subject in need thereof. In one example, the disclosure provides a method of treating a disease or condition in a subject, the method comprising administering the immunogenic composition or pharmaceutical composition of this disclosure to a subject in need thereof. In another example, the disclosure provides a method of preventing a disease or condition in a subject, the method comprising administering the immunogenic composition or pharmaceutical composition of this disclosure to a subject in need thereof.In another example, the disclosure provides a method for delaying the progression of a disease or condition in a subject, the method comprising administering the immunogenic composition or pharmaceutical composition of the present disclosure to a subject in need thereof. [001173] In one example, the subject suffers from an illness or condition. In one example, the subject has been diagnosed as having an illness or condition. In one example, the subject is receiving treatment for an illness or condition. [001174] In one example, the disease or condition is selected from the group consisting of influenza, COVID-19, SARS-CoV-2, respiratory syncytial virus (RSV), and acute respiratory distress syndrome (ARDS), or a combination thereof. In another example, the disease or condition is influenza and COVID-19. In another example, the disease or condition is influenza and RSV (Respiratory Syncytial Virus). In another example, the disease or condition is RSV (Respiratory Syncytial Virus) and COVID-19. In another example, the disease or condition is influenza, RSV (Respiratory Syncytial Virus), and COVID-19. In another example, the disease or condition is influenza and SARS-CoV-2. In another example, the disease or Petition 870260001818, dated 08 / 01 / 2026, page 166 / 357 162 / 291 The condition is SARS-CoV-2 and RSV (Respiratory Syncytial Virus). In another example, the disease or condition is SARS-CoV-2. In another example, the disease or condition is RSV (Respiratory Syncytial Virus). In another example, the disease or condition is influenza. In another example, the disease or condition is COVID-19. In another example, the disease or condition is ARDS (Acute Respiratory Distress Syndrome). [001175] A person skilled in the art will understand that, when considering the treatment, prevention, or delay of influenza progression, the immunogenic compositions described in this document will include at least one polynucleotide comprising a nucleotide sequence encoding an influenza antigen or an influenza antigenic polypeptide. The composition may include additional polynucleotide or polypeptide antigens, for example, from RSV or SARS-CoV-2, as described in this document. [001176] For example, an immunogenic composition suitable for the treatment, prevention or delay of influenza progression comprises: [001177] a) an RNA comprising a nucleotide sequence encoding an antigen of a SARS-CoV-2, wherein the nucleotide sequence is operationally linked to a regulatory element; and [001178] b) an antigenic polypeptide of influenza. [001179] In another example, an immunogenic composition suitable for the treatment, prevention or delay of influenza progression comprises: [001180] a) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is functionally linked to a regulatory element; and [001181] b) an antigenic polypeptide of SARS-CoV-2. [001182] In another example, an adequate immunogenic composition Petition 870260001818, dated 08 / 01 / 2026, page 167 / 357 163 / 291 for the treatment, prevention or delay of the progression of influenza includes: [001183] a) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is functionally linked to a regulatory element; and [001184] b) an influenza antigenic polypeptide. [001185] In another example, an immunogenic composition suitable for the treatment, prevention or delay of influenza progression comprises: [001186] a) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is functionally linked to a regulatory element; and [001187] b) an antigenic polypeptide of a respiratory syncytial virus (RSV). [001188] In another example, an immunogenic composition suitable for the treatment, prevention or delay of influenza progression comprises: [001189] a) an RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), wherein the nucleotide sequence is operationally linked to a regulatory element; and [001190] b) an antigenic polypeptide of influenza. [001191] In another example, an immunogenic composition suitable for the treatment, prevention or delay of influenza progression comprises: [001192] (i) an RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element; [001193] (ii) an RNA comprising a sequence of nucleotides Petition 870260001818, dated 08 / 01 / 2026, page 168 / 357 164 / 291 deos that encodes an influenza antigen, in which the nucleotide sequence is operationally linked to a regulatory element; and [001194] (iii) an antigenic polypeptide of SARS-CoV-2. [001195] In another example, an immunogenic composition suitable for the treatment, prevention or delay of influenza progression comprises: [001196] (i) an RNA comprising a nucleotide sequence encoding an antigen of a SARS-CoV-2, wherein the nucleotide sequence is operationally linked to a regulatory element; [001197] (ii) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and [001198] (iii) an antigenic polypeptide of a respiratory syncytial virus (RSV). [001199] In another example, an immunogenic composition suitable for the treatment, prevention or delay of influenza progression comprises: [001200] (i) an RNA comprising a nucleotide sequence encoding an antigen of a SARS-CoV-2, wherein the nucleotide sequence is operationally linked to a regulatory element; [001201] (ii) an RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and [001202] (iii) an influenza antigenic polypeptide. [001203] In another example, an adequate immunogenic composition Petition 870260001818, dated 08 / 01 / 2026, page 169 / 357 165 / 291 for the treatment, prevention or delay of the progression of influenza includes: [001204] (i) an RNA comprising a nucleotide sequence encoding an antigen of a SARS-CoV-2, wherein the nucleotide sequence is operationally linked to a regulatory element; [001205] (ii) an influenza antigenic polypeptide; and [001206] (iii) an antigenic polypeptide of respiratory syncytial virus (RSV). [001207] In another example, an immunogenic composition suitable for the treatment, prevention or delay of influenza progression comprises: [001208] (i) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; [001209] (ii) an antigenic polypeptide of SARS-CoV-2; and [001210] (iii) an antigenic polypeptide of respiratory syncytial virus (RSV). [001211] In another example, an immunogenic composition suitable for the treatment, prevention or delay of influenza progression comprises: [001212] (i) an RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), wherein the nucleotide sequence is operatively linked to a regulatory element; [001213] (ii) an antigenic polypeptide of SARS-CoV-2; and [001214] (iii) an antigenic polypeptide of influenza. [001215] A knowledgeable person will understand that, when considering the treatment, prevention, or delay of the progression of a SARS-CoV-2 or COVID-19 infection, the immunogenic compositions Petition 870260001818, dated 08 / 01 / 2026, page 170 / 357 166 / 291 described in this document will include at least one polynucleotide comprising a nucleotide sequence encoding an antigen of a SARS-CoV-2 or an antigenic polypeptide of a SARS-CoV-2. The composition may include additional polynucleotide or polypeptide antigens, for example, from influenza or RSV, as described in this document. [001216] For example, an immunogenic composition suitable for the treatment, prevention or delay of the progression of a SARS-CoV-2 or COVID-19 infection comprises: [001217] a) an RNA comprising a nucleotide sequence encoding an antigen of a SARS-CoV-2, wherein the nucleotide sequence is operationally linked to a regulatory element; and [001218] b) an antigenic polypeptide of influenza. [001219] In another example, an immunogenic composition suitable for the treatment, prevention, or delay of the progression of a SARS-CoV-2 or COVID-19 infection comprises: [001220] a) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is functionally linked to a regulatory element; and [001221] b) an antigenic polypeptide of SARS-CoV-2. [001222] In another example, an immunogenic composition suitable for the treatment, prevention, or delay of the progression of a SARS-CoV-2 or COVID-19 infection comprises: [001223] a) an RNA comprising a nucleotide sequence encoding an antigen of a SARS-CoV-2, wherein the nucleotide sequence is operationally linked to a regulatory element; and [001224] b) an antigenic polypeptide of SARS-CoV-2. [001225] In another example, an adequate immunogenic composition Petition 870260001818, dated 08 / 01 / 2026, page 171 / 357 167 / 291 for the treatment, prevention or delay of the progression of a SARS-CoV-2 or COVID-19 infection includes: [001226] a) an RNA comprising a nucleotide sequence encoding an antigen of a SARS-CoV-2, wherein the nucleotide sequence is operationally linked to a regulatory element; and [001227] b) an antigenic polypeptide of a respiratory syncytial virus (RSV). [001228] In another example, an immunogenic composition suitable for the treatment, prevention, or delay of the progression of a SARS-CoV-2 or COVID-19 infection comprises: [001229] a) an RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), wherein the nucleotide sequence is operationally linked to a regulatory element; and [001230] b) an antigenic polypeptide of SARS-CoV-2. [001231] In another example, an immunogenic composition suitable for the treatment, prevention, or delay of the progression of a SARS-CoV-2 or COVID-19 infection comprises: [001232] (i) an RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element; [001233] (ii) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and [001234] (iii) an antigenic polypeptide of SARS-CoV-2. [001235] In another example, an immunogenic composition suitable for the treatment, prevention, or delay of the progression of an in Petition 870260001818, dated 08 / 01 / 2026, page 172 / 357 168 / 291 infection by SARS-CoV-2 or COVID-19 includes: [001236] (i) an RNA comprising a nucleotide sequence encoding an antigen of a SARS-CoV-2, wherein the nucleotide sequence is operationally linked to a regulatory element; [001237] (ii) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and [001238] (iii) an antigenic polypeptide of a respiratory syncytial virus (RSV). [001239] In another example, an immunogenic composition suitable for the treatment, prevention, or delay of the progression of a SARS-CoV-2 or COVID-19 infection comprises: [001240] (i) an RNA comprising a nucleotide sequence encoding an antigen of a SARS-CoV-2, wherein the nucleotide sequence is operationally linked to a regulatory element; [001241] (ii) an RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and [001242] (iii) an antigenic polypeptide of influenza. [001243] In another example, an immunogenic composition suitable for the treatment, prevention, or delay of the progression of a SARS-CoV-2 or COVID-19 infection comprises: [001244] (i) an RNA comprising a nucleotide sequence encoding an antigen of a SARS-CoV-2, wherein the nucleotide sequence is operationally linked to a regulatory element; Petition 870260001818, dated 08 / 01 / 2026, page 173 / 357 169 / 291 [001245] (ii) an influenza antigenic polypeptide; and [001246] (iii) an antigenic polypeptide of respiratory syncytial virus (RSV). [001247] In another example, an immunogenic composition suitable for the treatment, prevention, or delay of the progression of a SARS-CoV-2 or COVID-19 infection comprises: [001248] (i) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; [001249] (ii) an antigenic polypeptide of SARS-CoV-2; and [001250] (iii) an antigenic polypeptide of respiratory syncytial virus (RSV). [001251] In another example, an immunogenic composition suitable for the treatment, prevention, or delay of the progression of a SARS-CoV-2 or COVID-19 infection comprises: [001252] (i) an RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), wherein the nucleotide sequence is operatively linked to a regulatory element; [001253] (ii) an antigenic polypeptide of SARS-CoV-2; and [001254] (iii) an antigenic polypeptide of influenza. [001255] A person knowledgeable will understand that, when considering the treatment, prevention, or delay of RSV progression, the immunogenic compositions described in this document will include at least one polynucleotide comprising a nucleotide sequence encoding an RSV antigen or an RSV antigenic polypeptide. The composition may include additional polynucleotide or polypeptide antigens, for example, from influenza or SARS-CoV-2, as described in this document. [001256] For example, an adequate immunogenic composition for Petition 870260001818, dated 08 / 01 / 2026, page 174 / 357 170 / 291 The treatment, prevention or delay of RSV progression includes: [001257] a) an RNA comprising a nucleotide sequence encoding an antigen of a SARS-CoV-2, wherein the nucleotide sequence is operationally linked to a regulatory element; and [001258] b) an RSV antigenic polypeptide. [001259] In another example, an immunogenic composition suitable for the treatment, prevention, or delay of RSV progression comprises: [001260] a) an RNA comprising a nucleotide sequence encoding an RSV antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and [001261] b) an antigenic polypeptide of SARS-CoV-2. [001262] In another example, an immunogenic composition suitable for the treatment, prevention, or delay of RSV progression comprises: [001263] a) an RNA comprising a nucleotide sequence encoding an RSV antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and [001264] b) an RSV antigenic polypeptide. [001265] In another example, an immunogenic composition suitable for the treatment, prevention, or delay of RSV progression comprises: [001266] a) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is functionally linked to a regulatory element; and [001267] b) an antigenic polypeptide of a respiratory syncytial virus (RSV). [001268] In another example, an adequate immunogenic composition Petition 870260001818, dated 08 / 01 / 2026, page 175 / 357 171 / 291 for the treatment, prevention or delay of RSV progression includes: [001269] a) an RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), wherein the nucleotide sequence is operationally linked to a regulatory element; and [001270] b) an antigenic polypeptide of influenza. [001271] In another example, an immunogenic composition suitable for the treatment, prevention, or delay of RSV progression comprises: [001272] (i) an RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element; [001273] (ii) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and [001274] (iii) an antigenic polypeptide of SARS-CoV-2. [001275] In another example, an immunogenic composition suitable for the treatment, prevention, or delay of RSV progression comprises: [001276] (i) an RNA comprising a nucleotide sequence encoding an antigen of a SARS-CoV-2, wherein the nucleotide sequence is operationally linked to a regulatory element; [001277] (ii) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and Petition 870260001818, dated 08 / 01 / 2026, page 176 / 357 172 / 291 [001278] (iii) an antigenic polypeptide of a respiratory syncytial virus (RSV). [001279] In another example, an immunogenic composition suitable for the treatment, prevention, or delay of RSV progression comprises: [001280] (i) an RNA comprising a nucleotide sequence encoding an antigen of a SARS-CoV-2, wherein the nucleotide sequence is operationally linked to a regulatory element; [001281] (ii) an RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and [001282] (iii) an antigenic polypeptide of influenza. [001283] In another example, an immunogenic composition suitable for the treatment, prevention, or delay of RSV progression comprises: [001284] (i) an RNA comprising a nucleotide sequence encoding an antigen of a SARS-CoV-2, wherein the nucleotide sequence is operationally linked to a regulatory element; [001285] (ii) an influenza antigenic polypeptide; and [001286] (iii) an antigenic polypeptide of respiratory syncytial virus (RSV). [001287] In another example, an immunogenic composition suitable for the treatment, prevention, or delay of RSV progression comprises: [001288] (i) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; Petition 870260001818, dated 08 / 01 / 2026, page 177 / 357 173 / 291 [001289] (ii) an antigenic polypeptide of SARS-CoV-2; and [001290] (iii) an antigenic polypeptide of respiratory syncytial virus (RSV). [001291] In another example, an immunogenic composition suitable for the treatment, prevention, or delay of RSV progression comprises: [001292] (i) an RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), wherein the nucleotide sequence is operatively linked to a regulatory element; [001293] (ii) an antigenic polypeptide of SARS-CoV-2; and [001294] (iii) an antigenic polypeptide of influenza. [001295] The present description provides a method for treating, preventing, or delaying the progression of a disease or condition in an individual, the method comprising the local co-administration of: [001296] (i) a polynucleotide comprising a nucleotide sequence encoding an antigen selected from the group consisting of a respiratory syncytial virus (RSV), influenza and a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and [001297] (ii) an antigenic polypeptide selected from the group consisting of RSV, influenza and SARS-CoV-2. [001298] In one example, the subject suffers from an illness or condition. In one example, the subject has been diagnosed as having an illness or condition. In one example, the subject is receiving treatment for an illness or condition. [001299] In another example, the method is for prophylaxis, for example, to prevent or reduce the risk of contracting a disease or condition. [001300] In one example, the disease or condition is selected from Petition 870260001818, dated 08 / 01 / 2026, page 178 / 357174 / 291 group consisting of influenza, COVID-19, SARS-CoV-2, respiratory syncytial virus (RSV), and acute respiratory distress syndrome (ARDS), or a combination thereof. In another example, the disease or condition is influenza and COVID-19. In another example, the disease or condition is influenza and RSV (Respiratory Syncytial Virus). In another example, the disease or condition is RSV (Respiratory Syncytial Virus) and COVID-19. In another example, the disease or condition is influenza, RSV (Respiratory Syncytial Virus), and COVID-19. In another example, the disease or condition is influenza and SARS-CoV-2. In another example, the disease or condition is SARS-CoV-2 and RSV (Respiratory Syncytial Virus). In another example, the disease or condition is SARS-CoV-2. In another example, the disease or condition is RSV (Respiratory Syncytial Virus). In another example, the disease or condition is the flu. In another example, the disease or condition is COVID-19. In another example, the disease or condition is ARDS (Acute Respiratory Distress Syndrome). [001301] A person knowledgeable will understand that, when intended to treat, prevent or delay the progression of influenza, the method described herein will include the administration of at least one polynucleotide comprising a nucleotide sequence encoding an influenza antigen or an influenza antigenic polypeptide. The composition may include additional polynucleotide or polypeptide antigens, for example, from RSV or SARS-CoV-2, as described in this document. [001302] For example, a method for the treatment, prevention or delay of the progression of an infection comprises the local co-administration of: [001303] a) an RNA comprising a nucleotide sequence encoding an antigen of a SARS-CoV-2, wherein the nucleotide sequence is operationally linked to a regulatory element; and Petition 870260001818, dated 08 / 01 / 2026, page 179 / 357 175 / 291 [001304] b) an antigenic polypeptide of influenza. [001305] In another example, the method involves managing: [001306] a) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is functionally linked to a regulatory element; and [001307] b) an antigenic polypeptide of SARS-CoV-2. [001308] In another example, the method comprises administering: [001309] a) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is functionally linked to a regulatory element; and [001310] b) an influenza antigenic polypeptide. [001311] In another example, the method involves managing: [001312] a) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is functionally linked to a regulatory element; and [001313] b) an antigenic polypeptide of a respiratory syncytial virus (RSV). [001314] In another example, the method comprises administering: [001315] a) an RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), wherein the nucleotide sequence is operationally linked to a regulatory element; and [001316] b) an antigenic polypeptide of influenza. [001317] In another example, the method involves managing: [001318] (i) an RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operatively linked to a regulatory element; [001319] (ii) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nu sequence Petition 870260001818, dated 08 / 01 / 2026, page 180 / 357 176 / 291 nucleotides are operationally linked to a regulatory element; and [001320] (iii) an antigenic polypeptide of SARS-CoV-2. [001321] In another example, the method involves managing: [001322] (i) an RNA comprising a nucleotide sequence encoding an antigen of a SARS-CoV-2, wherein the nucleotide sequence is operationally linked to a regulatory element; [001323] (ii) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and [001324] (iii) an antigenic polypeptide of a respiratory syncytial virus (RSV). [001325] In another example, the method involves managing: [001326] (i) an RNA comprising a nucleotide sequence encoding an antigen of a SARS-CoV-2, wherein the nucleotide sequence is operationally linked to a regulatory element; [001327] (ii) an RNA comprising a nucleotide sequence encoding a respiratory syncytial virus (RSV) antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and [001328] (iii) an influenza antigenic polypeptide. [001329] In another example, the method involves managing: [001330] (i) an RNA comprising a nucleotide sequence encoding an antigen of a SARS-CoV-2, wherein the nucleotide sequence is operationally linked to a regulatory element; [001331] (ii) an influenza antigenic polypeptide; and Petition 870260001818, dated 08 / 01 / 2026, page 181 / 357 177 / 291 [001332] (iii) an antigenic polypeptide of respiratory syncytial virus (RSV). [001333] In another example, the method involves managing: [001334] (i) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; [001335] (ii) an antigenic polypeptide of SARS-CoV-2; and [001336] (iii) an antigenic polypeptide of respiratory syncytial virus (RSV). [001337] In another example, the method involves managing: [001338] (i) an RNA comprising a nucleotide sequence encoding an antigen of a respiratory syncytial virus (RSV), wherein the nucleotide sequence is operatively linked to a regulatory element; [001339] (ii) an antigenic polypeptide of SARS-CoV-2; and [001340] (iii) an antigenic polypeptide of influenza. [001341] A knowledgeable person will understand that when considering the treatment, prevention, or delay in the progression of an influenza infection and / or RSV infection and / or SARS-CoV-2 or COVID-19 infection. [001342] Suitable combinations of antigens and / or antigens themselves are described in this document in relation to immunogenic compositions and should be considered applicable, mutatis mutandis, to the treatment methods described herein. [001343] In one example, the present invention describes a method for treating, preventing or delaying the progression of an influenza and / or RSV infection, comprising the local co-administration of: [001344] (i) an RSV F protein; and [001345] (ii) a sa-mRNA encoding an influenza HA. [001346] In one example, the present invention describes a method Petition 870260001818, dated 01 / 08 / 2026, p. 182 / 357 178 / 291 to treat, prevent or delay the progression of an influenza and / or RSV infection, comprising the local co-administration of: [001347] (i) an RSV F protein; and [001348] (ii) a sa-mRNA encoding an influenza HA and NA. [001349] In one example, the present invention describes a method for treating, preventing or delaying the progression of an influenza and / or RSV infection, comprising the local co-administration of: [001350] (i) an F protein of the RSV; and [001351] (ii) a plurality of sa-mRNAs, each sa-mRNA encoding an influenza HA. [001352] In one example, the present invention describes a method for treating, preventing or delaying the progression of an influenza and / or RSV infection, comprising the local co-administration of: [001353] (i) an RSV F protein; and [001354] (ii) a plurality of sa-mRNAs, each sa-mRNA encoding an influenza HA and NA. [001355] In one example, the present invention describes a method for treating, preventing or delaying the progression of an influenza and / or RSV infection, comprising the local co-administration of: [001356] (i) an RSV F protein; and [001357] (ii) three or more sa-mRNAs, each sa-mRNA encoding an influenza HA. [001358] In one example, the present invention describes a method for treating, preventing or delaying the progression of an influenza and / or RSV infection, comprising the local co-administration of: [001359] (i) an RSV F protein; and [001360] (ii) three or more sa-mRNAs, each sa-mRNA encoding an influenza HA and NA. [001361] (i) an F protein of the RSV; and [001362] (ii) four or more sa-mRNAs, each sa-mRNA encoding Petition 870260001818, dated 01 / 08 / 2026, p. 183 / 357 179 / 291 a flu HA. [001363] In one example, the present invention describes a method for treating, preventing or delaying the progression of an influenza and / or RSV infection, comprising the local co-administration of: [001364] (i) an RSV F protein; and [001365] (ii) four or more sa-mRNAs, each sa-mRNA encoding an influenza HA and NA. [001366] By way of example, the present description provides a method for inducing an immune response in an individual, the method comprising administering a pharmaceutical composition disclosed herein, an immunogenic composition disclosed herein or a vaccine disclosed herein to an individual in need thereof, or performing a method described herein. [001367] By way of example, the present description describes the use of a pharmaceutical composition disclosed herein, an immunogenic composition disclosed herein or a vaccine disclosed herein in the manufacture of a medicament to induce an immune response in an individual who needs it. [001368] By way of example, the present description discloses a pharmaceutical composition, an immunogenic composition or a vaccine for use in inducing an immune response in an individual who needs it. [001369] In one example, the composition or method of disclosure induces a humoral immune response in the subject. For example, the humoral immune response is an antibody-mediated immune response. For example, the production of neutralizing antibodies. In another example, the composition induces a cell-mediated immune response. For example, the cell-mediated immune response includes the activation of antigen-specific cytotoxic T cells. For example, the T cells are CD4 T cells and / or CD8 T cells. In one example, the T cells Petition 870260001818, dated 08 / 01 / 2026, page 184 / 357 180 / 291 are CD4 T cells. In another example, the T cells are CD8 T cells. In yet another example, the T cells are both CD4 and CD8 T cells. [001370] In one example, administration of a pharmaceutical composition disclosed herein, an immunogenic composition disclosed herein, or a vaccine as described in this description induces an immune response mediated by CD4 T cells. [001371] In one example, administration of a pharmaceutical composition, an immunogenic composition disclosed herein, or a vaccine as described in this description induces an immune response mediated by CD8 T cells. [001372] In one example, administration of a pharmaceutical composition disclosed herein, an immunogenic composition disclosed herein, or a vaccine of the present description induces an immune response mediated by CD4 and CD8 T cells. [001373] In one example, the CD4 T cell-mediated immune response is a Th0, Th1, and / or Th2 response. For example, the CD4 T cell-mediated immune response is a Th0 response. In another example, the CD4 T cell-mediated immune response is a Th1 response. In yet another example, the CD4 T cell-mediated immune response is a Th2 response. In one example, the CD4 T cell-mediated immune response is a Th0 and Th1 response. In another example, the CD4 T cell-mediated immune response is a Th0 and Th2 response. In yet another example, the CD4 T cell-mediated immune response is a Th1 and Th2 response. In yet another example, the CD4 T cell-mediated immune response is a Th0, Th1, and Th2 response. [001374] In one example, the CD8 T cell-mediated immune response can be a Th0, Th1, and / or Th2 response. For example, the CD8 T cell-mediated immune response is a Th0 response. In another example, the CD8 T cell-mediated immune response is a Th1 response. In yet another example, the CD8 T cell-mediated immune response Petition 870260001818, dated 01 / 08 / 2026, pp. 185 / 357 181 / 291 CD8 is a Th2 response. In one example, the immune response mediated by CD8 T cells is a Th0 and Th1 response. In another example, the immune response mediated by CD8 T cells is a Th0 and Th2 response. In another example, the immune response mediated by CD8 T cells is a Th1 and Th2 response. In another example, the immune response mediated by CD8 T cells is a Th0, Th1, and Th2 response. [001375] In one example, the compositions described in this document are able to modify the Th2:Th1 ratio. In one example, the compositions described in this document decrease the Th2:Th1 ratio. [001376] In one example, Th0 response cytokines express interleukin 2 (IL2+) and / or tumor necrosis factor alpha (TNFa+); and / or are negative for interferon gamma (IFNg-), IL5- and / or IL13-. For example, the cytokine is IL2+. In another example, the cytokine is TNFa+. In one example, the cytokine is IFNg-. In another example, the cytokine is IL5-. In yet another example, the cytokine is IL13-. [001377] In one example, Th1 response cytokines express interferon gamma (IFNg+) and / or are negative for IL5- and / or IL13-. For example, the cytokine is IFNg+. In another example, the cytokine is IL5-. In yet another example, the cytokine is IL13-. [001378] In one example, Th2 response cytokines express IL5+ and / or IL13+ and / or are negative for IFNγ. For example, the cytokine is IL5+. In another example, the cytokine is IL13+. For example, the cytokine is IFNγ-. [001379] By ...

Claims

1. Immunogenic composition, characterized in that it comprises: a) an RNA comprising a nucleotide sequence encoding an antigen selected from the group consisting of a respiratory syncytial virus (RSV), an influenza virus and a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operably linked to a regulatory element; and b) a polypeptide of antigen selected from the group consisting of an RSV, an influenza virus and a SARS-CoV-2.

2. Immunogenic composition, according to claim 1, characterized in that it comprises: a) an RNA comprising a nucleotide sequence encoding an antigen of an RSV, wherein the nucleotide sequence is operationally linked to a regulatory element; and b) a polypeptide antigen of a SARS-CoV-2.

3. Immunogenic composition, according to claim 1, characterized in that it comprises: a) an RNA comprising a nucleotide sequence encoding an antigen of a SARS-CoV-2, wherein the nucleotide sequence is operationally linked to a regulatory element; and b) an RSV antigen polypeptide.

4. Immunogenic composition, according to claim 1, characterized in that it comprises: a) an RNA comprising a nucleotide sequence encoding an antigen of SARS-CoV-2, wherein the nucleotide sequence is operationally linked to a regulatory element; and Petition 870260001818, dated 08 / 01 / 2026, page 297 / 357 2 / 15 b) an influenza antigen polypeptide.

5. Immunogenic composition, according to claim 1, characterized in that it comprises: a) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and b) a polypeptide antigen of a SARS-CoV-2.

6. Immunogenic composition, according to claim 1, characterized in that it comprises: a) an RNA comprising a nucleotide sequence encoding an influenza antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and b) an RSV antigen polypeptide.

7. Immunogenic composition, according to claim 1, characterized in that it comprises: a) an RNA comprising a nucleotide sequence encoding an RSV antigen, wherein the nucleotide sequence is operationally linked to a regulatory element; and b) an influenza antigen polypeptide.

8. Immunogenic composition, according to claim 1, characterized in that it further comprises a second RNA comprising a nucleotide sequence encoding an antigen selected from the group consisting of an RSV, an influenza virus and a SARS-CoV-2, wherein the nucleotide sequence is operationally linked to a regulatory element.

9. Immunogenic composition, according to claim 1, characterized in that it further comprises a second antigen polypeptide selected from the group consisting of an RSV, an influenza virus and a SARS-CoV-2.

10. Immunogenic composition, according to claim 2 or 3, characterized in that it further comprises a second RNA comprising a nucleotide sequence encoding an influenza antigen, operationally linked to a regulatory element.

11. Immunogenic composition, according to claim 10, characterized in that it comprises, in the order from 5' to 3': (i) RNA comprising a nucleotide sequence encoding an RSV or SARS-CoV-2 antigen; (ii) RNA comprising a nucleotide sequence encoding an influenza antigen.

12. Immunogenic composition, according to claim 10, characterized in that it comprises, in the order from 5' to 3': (i) RNA comprising a nucleotide sequence encoding an influenza antigen; and (ii) RNA comprising a nucleotide sequence encoding an RSV or SARS-CoV-2 antigen.

13. Immunogenic composition, according to claim 2 or 3, characterized in that it further comprises a second influenza antigen polypeptide.

14. Immunogenic composition, according to claim 4 or 5, characterized in that it further comprises a second RNA comprising a nucleotide sequence encoding an RSV antigen, operationally linked to a regulatory element.

15. Immunogenic composition, according to claim 14, characterized in that it comprises, in the order of 5' to 3': (i) RNA comprising a nucleotide sequence that encodes an antigen of SARS-CoV-2; (ii) RNA comprising a nucleotide sequence that encodes an antigen of RSV.

16. Immunogenic composition, according to claim 14, characterized in that it comprises, in the order of 5' to 3': (i) RNA containing a nucleotide sequence encoding an RSV antigen; and (ii) RNA comprising a nucleotide sequence encoding an antigen of SARS-CoV-2.

17. Immunogenic composition, according to claim 4 or 5, characterized in that it further comprises a second RSV antigen polypeptide.

18. Immunogenic composition, according to claim 6 or 7, characterized in that it further comprises a second RNA comprising a nucleotide sequence encoding an antigen of SARS-CoV-2, operationally linked to a regulatory element.

19. Immunogenic composition, according to claim 18, characterized in that it comprises, in the order of 5' to 3': (i) RNA comprising a nucleotide sequence encoding an antigen of SARS-CoV-2; (ii) RNA comprising a nucleotide sequence encoding an influenza antigen.

20. Immunogenic composition, according to claim 18, characterized in that it comprises, in the order of 5' to 3': (i) RNA comprising a nucleotide sequence encoding an influenza antigen; and Petition 870260001818, dated 08 / 01 / 2026, page 300 / 357 5 / 15 (ii) RNA comprising a nucleotide sequence encoding an antigen of SARS-CoV-2.

21. Immunogenic composition, according to claim 6 or 7, characterized in that it further comprises a second SARS-CoV-2 antigen polypeptide.

22. Immunogenic composition, according to any one of claims 8, 10 to 12, 14 to 16 or 18 to 20, characterized in that it comprises a plurality of RNAs, wherein each self-replicating RNA encodes different polypeptide sequences.

23. Immunogenic composition, according to any one of claims 1 to 22, characterized in that the regulatory element is selected from the group consisting of a promoter, an internal ribosome entry site (IRES), or a Kozak consensus sequence, or a combination thereof.

24. Immunogenic composition, according to claim 23, characterized in that the promoter is a subgenomic promoter (SG).

25. Immunogenic composition, according to claim 24, characterized in that the SG promoter is a minimal SG promoter.

26. Immunogenic composition, according to claim 24, characterized in that the SG promoter is an extended SG promoter.

27. Immunogenic composition, according to claim 25, characterized in that the minimal SG promoter is encoded by a sequence established in SEQ ID NO:

13.

28. Immunogenic composition, according to claim 26, characterized in that the extended SG promoter is encoded by a sequence established in SEQ ID NO:

14.

29. Immunogenic composition, according to claim 23, characterized in that the nucleotide sequence encoding an antigen is operationally linked to an IRES located 5' from the nucleotide sequence encoding the antigen.

30. Immunogenic composition, according to claim 23 or 29, characterized in that the IRES is an IRES of encephalomyocarditis virus (EMCV), poliovirus (PV), human enterovirus, foot-and-mouth disease virus (FMDV), hepatitis C virus (HCV), classical swine fever virus (CSFV), murine leukemia virus (MLV), simian immunodeficiency virus (SIV), eukaryotic translation initiation factor 4G (elF4G), death-associated protein 5 (DAP5), cellular Myc (c-Myc), NF-κB repression factor (NRF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF-2), platelet-derived growth factor B (PDGF-B), Antennapedia, X-linked apoptosis inhibitor (XIAP or Apaf-1), immunoglobulin heavy chain binding protein BiP, or growth factor of fibroblasts 1a (FGF1A), GTX, or a combination thereof.

31. Immunogenic composition, according to claim 30, characterized in that the EMCV IRES is a wild-type IRES encoded by a sequence established in SEQ ID NO:

16.

32. Immunogenic composition, according to any one of claims 1, 2, 7, 8, 11, 12 or 14 to 16, characterized in that the nucleotide sequence encoding an RSV antigen has a sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95% identical to SEQ ID NO:1 or 3.

33. Immunogenic composition, according to any of the preceding claims, characterized in that the nucleotide sequence encoding an RSV antigen has the sequence established in SEQ ID NO:1 or 3. Petition 870260001818, dated 08 / 01 / 2026, pp. 302 / 357 7 / 15 34. Immunogenic composition, according to any one of claims 1, 3, 4, 8, 12, 15, 16, 18, 19 or 20, characterized in that the nucleotide sequence encoding an antigen of a SARS-CoV-2 has a sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95% identical to SEQ ID NO: 9 or 11.

35. Immunogenic composition, according to any one of claims 1, 3, 4, 8, 12, 15, 16 or 18 to 20, characterized in that the nucleotide sequence encoding an antigen of a SARS-CoV-2 has the sequence established in SEQ ID NO: 9 or 11.

36. Immunogenic composition, according to any one of claims 1, 5, 6, 8, 10 to 12, 19 or 20, characterized in that the nucleotide sequence encoding an influenza antigen has a sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95% identical to SEQ ID NO: 5 or 7.

37. Immunogenic composition, according to any one of claims 1, 5, 6, 8, 10 to 12, 19 or 20, characterized in that the nucleotide sequence encoding an influenza antigen has the sequence set at SEQ ID NO: 5 or 7.

38. Immunogenic composition, according to any one of claims 1, 3, 6, 9 or 17, characterized in that the antigen polypeptide of an RSV has an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95% identical to SEQ ID NO: 2 or 4.

39. Immunogenic composition, according to any one of claims 1, 3, 6, 9 or 17, characterized in that the antigen polypeptide of an RSV has the amino acid sequence set forth in SEQ ID NO: 2 or 4.

40. Immunogenic composition, according to any one of claims 1, 2, 5, 9 or 21, characterized in that the antigen polypeptide of a SARS-CoV-2 has an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95% identical to SEQ ID NO: 10 or 12.

41. Immunogenic composition, according to any one of claims 1, 2, 5, 9 or 21, characterized in that the antigen polypeptide of a SARS-CoV-2 has the amino acid sequence established at SEQ ID NO: 10 or 12.

42. Immunogenic composition, according to any one of claims 1, 4, 7, 9 or 13, characterized in that the influenza antigen polypeptide has an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95% identical to SEQ ID NO: 6 or 8.

43. Immunogenic composition, according to any one of claims 1, 4, 7, 9 or 13, characterized in that the influenza antigen polypeptide has the amino acid sequence established in SEQ ID NO: 6 or 8.

44. Immunogenic composition, according to any one of claims 1 to 43, characterized in that the RNA is selected from the group consisting of cRNA or a self-replicating RNA.

45. Immunogenic composition, according to claim 44, characterized in that the self-replicating RNA is from an alphavirus, optionally selected from the group consisting of Semliki Forest Virus (SFV), Sindbis Virus (SIN), and Venezuelan Equine Encephalitis Virus (VEE), and combinations thereof. Petition 870260001818, dated 08 / 01 / 2026, pp. 304 / 357 9 / 15 46. ​​Immunogenic composition, according to any one of claims 1 to 45, characterized in that it further comprises an adjuvant.

47. Immunogenic composition, according to claim 46, characterized in that the adjuvant is MF59.

48. Immunogenic composition, according to any one of claims 1 to 47, characterized in that it further comprises an additional coding RNA or a polypeptide selected from: (i) one or more antigens; (ii) one or more immunopotentiating agents; (iii) one or more chemoattractants; and / or (iv) one or more targeting molecules.

49. Pharmaceutical composition, characterized in that it comprises an immunogenic composition, as defined in any one of claims 1 to 48, and a pharmaceutically acceptable carrier.

50. Pharmaceutical composition, according to claim 49, characterized in that it further comprises a lipid nanoparticle (LNP), a polymeric microparticle or an oil-in-water emulsion.

51. Pharmaceutical composition, according to claim 50, characterized in that the RNA is encapsulated, bound or adsorbed onto an LNP, a polymeric microparticle or an oil-in-water emulsion.

52. Pharmaceutical composition, according to any one of claims 49 to 51, characterized in that each RNA is formulated together with the LNP.

53. Pharmaceutical composition, according to any one of claims 49 to 51, characterized in that each RNA is formulated separately in LNP.

54. Immunogenic composition, according to any one of claims 1 to 48, or pharmaceutical composition, according to any one of claims 49 to 53, characterized in that it is for use as a vaccine.

55. Vaccine, characterized in that it comprises the pharmaceutical composition, as defined in any one of claims 49 to 53, or the immunogenic composition, as defined in any one of claims 1 to 48.

56. A method for treating, preventing, or delaying the progression of a disease or condition in an individual in need thereof, characterized in that it comprises administering the immunogenic composition, as defined in any one of claims 1 to 48, the pharmaceutical composition, as defined in any one of claims 49 to 53, or the vaccine, as defined in claim 55, to the individual.

57. Use of the immunogenic composition, as defined in any one of claims 1 to 48, of the pharmaceutical composition, as defined in any one of claims 49 to 53, or of the vaccine, as defined in claim 55, characterized in that it is for the manufacture of a medicament to treat, prevent or delay the progression of a disease or condition in an individual who needs it.

58. An immunogenic composition, according to any one of claims 1 to 48, a pharmaceutical composition, according to any one of claims 49 to 53, or a vaccine, according to claim 55, characterized in that it is for use in the treatment, prevention or retardation of the progression of a disease or condition in an individual who needs it.

59. Method, according to claim 56, the use, according to Petition 870260001818, dated 08 / 01 / 2026, page 306 / 357 11 / 15, or the pharmaceutical composition, the immunogenic composition or the vaccine for use, according to claim 58, characterized in that the disease or condition is selected from influenza, RSV, SARS-CoV-2 infection and / or COVID-19.

60. A method for inducing an immune response in an individual, characterized in that it comprises administering the immunogenic composition, as defined in any one of claims 1 to 48, the pharmaceutical composition, as defined in any one of claims 49 to 53, or the vaccine, as defined in claim 55, to an individual in need thereof.

61. Use of the immunogenic composition, as defined in any one of claims 1 to 48, of the pharmaceutical composition, as defined in any one of claims 49 to 53, or of the vaccine, as defined in claim 55, characterized in that it is used in the manufacture of a medicament to induce an immune response in an individual who needs it.

62. Immunogenic composition, according to any one of claims 1 to 48, pharmaceutical composition, according to any one of claims 49 to 53, or vaccine, according to claim 55, characterized in that it is for use in inducing an immune response in an individual who needs it.

63. A method according to claim 60, a use according to claim 61, or an immunogenic composition, pharmaceutical composition or vaccine for use according to claim 62, characterized in that the immune response is a cell-mediated immune response, optionally a Th2 response.

64. Method for reducing the viral load in an individual, characterized in that it comprises administering the immunogenic composition, as defined in any of claims 1 to 48, the pharmaceutical composition, as defined in any of claims 49 to 53, or the vaccine, as defined in claim 55, to the individual who needs it.

65. Use of the immunogenic composition, as defined in any one of claims 1 to 48, of the pharmaceutical composition, as defined in any one of claims 49 to 53, or of the vaccine, as defined in claim 55, characterized in that it is in the preparation of a medicament to reduce the viral load in an individual who needs it.

66. Immunogenic composition, according to any one of claims 1 to 48, pharmaceutical composition, according to any one of claims 49 to 53, or vaccine, according to claim 55, characterized in that it is for use in reducing the viral load in an individual in need thereof.

67. A method for inducing a Th1 immune response in an individual in need thereof, characterized in that it comprises administering the pharmaceutical composition, as defined in any one of claims 49 to 53, or the vaccine, as defined in claim 55, to the individual.

68. Use of the pharmaceutical composition, as defined in any one of claims 49 to 53, or of the vaccine, as defined in claim 55, characterized in that it is in the preparation of a medicament to induce a Th1 immune response in an individual.

69. Pharmaceutical composition, according to any one of claims 49 to 53, or the vaccine, according to claim 55, characterized in that it is for use in inducing a Th1 immune response in an individual.

70. Method, according to any of the claims Petition 870260001818, dated 08 / 01 / 2026, page 308 / 357 13 / 15 tions 56, 59, 60, 63, 64 or 67, the use, according to any of the claims 57, 59, 61, 63, 65 or 68, or the immunogenic composition, pharmaceutical composition or vaccine for use, according to any of the claims 58, 59, 62, 63, 66 or 69, characterized in that the individual is a human being 18 years of age or older.

71. A method for treating, preventing, or delaying the progression of respiratory syncytial virus (RSV) in an infant, characterized in that it comprises administering the immunogenic composition, as defined in any one of claims 1, 2, 3, 6 to 9, 11, 12, or 14 to 17, or a pharmaceutical composition or vaccine thereof, to the infant.

72. Use of the immunogenic composition, as defined in any one of claims 1, 2, 3, 6 to 9, 11, 12 or 14 to 17, or of a pharmaceutical composition or vaccine derived therefrom, characterized in that it is in the preparation of a medicament for treating, preventing or delaying the progression of respiratory syncytial virus (RSV) in an infant.

73. Immunogenic composition, according to any one of claims 1, 2, 3, 6 to 9, 11, 12 or 14 to 17, or a pharmaceutical composition or vaccine thereof, characterized in that it is for use in the treatment, prevention or delay of the progression of respiratory syncytial virus (RSV) in an infant.

74. A method for inducing an immune response in an infant, characterized in that it comprises administering the immunogenic composition, as defined in any one of claims 1 to 48, the pharmaceutical composition, as defined in any one of claims 49 to 53, or the vaccine, as defined in claim 55, to the infant.

75. Use of the immunogenic composition, as defined in Petition 870260001818, dated 08 / 01 / 2026, pp. 309 / 357 14 / 15, any of claims 1 to 48, of the pharmaceutical composition, as defined in any of claims 49 to 53, or of the vaccine, as defined in claim 55, characterized in that it is for the preparation of a medicament to induce an immune response in an infant.

76. Immunogenic composition, according to any one of claims 1 to 48, pharmaceutical composition, according to any one of claims 49 to 53, or vaccine, according to claim 55, characterized in that it is for use in inducing an immune response in an infant.

77. A method according to claim 74, a use according to claim 75, or a pharmaceutical composition, immunogenic composition, or vaccine for use according to claim 76, characterized in that the immune response is a cell-mediated immune response, optionally a Th1 response.

78. A method according to claim 71, a use according to claim 72, or an immunogenic composition, pharmaceutical composition or vaccine for use according to claim 73, characterized in that the infant is between about 1 month and 12 months old.

79. A method according to any one of claims 56, 59, 60, 63, 64, 67, 70, 71, 74 or 77, the use according to any one of claims 57, 59, 61, 63, 65, 68, 70, 72, 75, 77 or 78, or the pharmaceutical composition, immunogenic composition or vaccine for use according to any one of claims 58, 59, 62, 63, 66, 69, 70, 73, 76 to 78, characterized in that the vaccine or composition is administered in a single-dose regimen.

80. Method, according to any of claims 56, 59, 60, 63, 64, 67, 70, 71, 74 or 77, the use, according to any of claims 57, 59, 61, 63, 65, 68, 70, 72, 75, 77 Petition 870260001818, dated 08 / 01 / 2026, page. 310 / 357 15 / 15 or 78 or the pharmaceutical composition, immunogenic composition or vaccine for use, according to any of claims 58, 59, 62, 63, 66, 69, 70, 73, 76 to 78, characterized in that the composition or vaccine is administered in a two, three or four dose regimen, wherein the doses are administered approximately 1, 2 or 3 months apart.

81. Kit, characterized in that it comprises: (a) the immunogenic composition, as defined in any one of claims 1 to 48, the pharmaceutical composition, as defined in any one of claims 49 to 53, or the vaccine, as defined in claim 55; (b) instructions for use thereof; and, optionally, (c) a diluent.

82. A method for treating, preventing, or delaying the progression of a disease or condition in an individual, characterized in that it comprises locally co-administering (i) a polynucleotide comprising a nucleotide sequence encoding an antigen selected from the group consisting of a respiratory syncytial virus (RSV), influenza, and a severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the nucleotide sequence is operationally linked to a regulatory element; and (ii) a polypeptide of antigen selected from the group consisting of an RSV, influenza, and SARS-CoV-2.